{ "documentInfo": { "documentType": "https://xbrl.org/2021/xbrl-json", "features": { "xbrl:canonicalValues": true }, "namespaces": { "ifrs-full": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "iso4217": "http://www.xbrl.org/2003/iso4217", "scheme": "http://standards.iso.org/iso/17442", "xbrl": "https://xbrl.org/2021", "xbrli": "http://www.xbrl.org/2003/instance" }, "taxonomy": [ "http://vicorepharma.com/2022-12-31/549300KTNBPTZLF01130-2022-12-31.xsd" ] }, "facts": { "f3872": { "value": "Vicore Pharma Holding AB (publ.),", "dimensions": { "concept": "ifrs-full:NameOfReportingEntityOrOtherMeansOfIdentification", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-2-1": { "value": "Vicore\u2019s operationsVicore is an innovative Swedishclinical-stage pharmaceutical company dedicated to creating life-changingtreatments in diseases where the angiotensin II type 2 receptor (AT2 receptor) has a central role in stopping and reversing disease pathology. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available smallmolecule angiotensin II type 2 receptor agonist (ATRAG). Almee\u2122 (an inves-tigational medical device in clinical development) is a digital therapeutic(DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe coughassociated with IPF. With our unique expertise in the ATRAG biology we fuel our pipeline with several new assets fora variety of diseases, some of which could be partnered while others can be taken to the market by Vicore.", "dimensions": { "concept": "ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f5641": { "value": "68100000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5644": { "value": "67427000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRights", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5650": { "value": "54000", "decimals": -3, "dimensions": { "concept": "ifrs-full:PropertyPlantAndEquipment", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5653": { "value": "84000", "decimals": -3, "dimensions": { "concept": "ifrs-full:PropertyPlantAndEquipment", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5660": { "value": "63000", "decimals": -3, "dimensions": { "concept": "ifrs-full:RightofuseAssets", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5663": { "value": "317000", "decimals": -3, "dimensions": { "concept": "ifrs-full:RightofuseAssets", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5670": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5673": { "value": "5409000", "decimals": -3, "dimensions": { "concept": "ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5679": { "value": "68217000", "decimals": -3, "dimensions": { "concept": "ifrs-full:NoncurrentAssets", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5682": { "value": "73237000", "decimals": -3, "dimensions": { "concept": "ifrs-full:NoncurrentAssets", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5688": { "value": "2180000", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherCurrentReceivables", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5691": { "value": "1417000", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherCurrentReceivables", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5698": { "value": "5867000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncomeIncludingCurrentContractAssets", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5701": { "value": "5034000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncomeIncludingCurrentContractAssets", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5708": { "value": "4940000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentInvestments", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5711": { "value": "77281000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentInvestments", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5718": { "value": "256803000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5721": { "value": "294199000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5727": { "value": "269790000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentAssets", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5730": { "value": "377931000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentAssets", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5735": { "value": "338007000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Assets", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5738": { "value": "451168000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Assets", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5747": { "value": "40924000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IssuedCapital", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5750": { "value": "35880000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IssuedCapital", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5755": { "value": "1210811000", "decimals": -3, "dimensions": { "concept": "ifrs-full:AdditionalPaidinCapital", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5759": { "value": "1021666000", "decimals": -3, "dimensions": { "concept": "ifrs-full:AdditionalPaidinCapital", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5764": { "value": "-962652000", "decimals": -3, "dimensions": { "concept": "ifrs-full:RetainedEarnings", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5768": { "value": "-674230000", "decimals": -3, "dimensions": { "concept": "ifrs-full:RetainedEarnings", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5775": { "value": "289083000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5778": { "value": "383316000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5787": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:NoncurrentLeaseLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5790": { "value": "320000", "decimals": -3, "dimensions": { "concept": "ifrs-full:NoncurrentLeaseLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5797": { "value": "1600000", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherLongtermProvisions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5800": { "value": "600000", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherLongtermProvisions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5807": { "value": "905000", "decimals": -3, "dimensions": { "concept": "ifrs-full:DeferredTaxLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5810": { "value": "1210000", "decimals": -3, "dimensions": { "concept": "ifrs-full:DeferredTaxLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5816": { "value": "2505000", "decimals": -3, "dimensions": { "concept": "ifrs-full:NoncurrentLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5819": { "value": "2130000", "decimals": -3, "dimensions": { "concept": "ifrs-full:NoncurrentLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5827": { "value": "65000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentLeaseLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5830": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentLeaseLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5838": { "value": "23495000", "decimals": -3, "dimensions": { "concept": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5841": { "value": "23984000", "decimals": -3, "dimensions": { "concept": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5846": { "value": "760000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentTaxLiabilitiesCurrent", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5849": { "value": "335000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentTaxLiabilitiesCurrent", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5854": { "value": "3751000", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherCurrentLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5857": { "value": "1112000", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherCurrentLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5864": { "value": "127000", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherShorttermProvisions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5867": { "value": "152000", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherShorttermProvisions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5874": { "value": "18221000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentAccrualsAndCurrentDeferredIncomeIncludingCurrentContractLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5877": { "value": "40139000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentAccrualsAndCurrentDeferredIncomeIncludingCurrentContractLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5883": { "value": "46419000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5886": { "value": "65722000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CurrentLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5893": { "value": "48924000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Liabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5896": { "value": "67852000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Liabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5902": { "value": "338007000", "decimals": -3, "dimensions": { "concept": "ifrs-full:EquityAndLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5905": { "value": "451168000", "decimals": -3, "dimensions": { "concept": "ifrs-full:EquityAndLiabilities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5924": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:Revenue", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5927": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:Revenue", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5932": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:GrossProfit", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5935": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:GrossProfit", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5942": { "value": "28380000", "decimals": -3, "dimensions": { "concept": "ifrs-full:AdministrativeExpense", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5945": { "value": "20204000", "decimals": -3, "dimensions": { "concept": "ifrs-full:AdministrativeExpense", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5952": { "value": "9149000", "decimals": -3, "dimensions": { "concept": "ifrs-full:SalesAndMarketingExpense", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5955": { "value": "1404000", "decimals": -3, "dimensions": { "concept": "ifrs-full:SalesAndMarketingExpense", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5962": { "value": "249965000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ResearchAndDevelopmentExpense", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5965": { "value": "271812000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ResearchAndDevelopmentExpense", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5972": { "value": "-3231000", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherOperatingIncomeExpense", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5975": { "value": "-1398000", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherOperatingIncomeExpense", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5981": { "value": "-290725000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5984": { "value": "-294818000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5991": { "value": "2395000", "decimals": -3, "dimensions": { "concept": "ifrs-full:FinanceIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f5994": { "value": "646000", "decimals": -3, "dimensions": { "concept": "ifrs-full:FinanceIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6001": { "value": "476000", "decimals": -3, "dimensions": { "concept": "ifrs-full:FinanceCosts", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6004": { "value": "2563000", "decimals": -3, "dimensions": { "concept": "ifrs-full:FinanceCosts", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6009": { "value": "1919000", "decimals": -3, "dimensions": { "concept": "ifrs-full:FinanceIncomeCost", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6012": { "value": "-1917000", "decimals": -3, "dimensions": { "concept": "ifrs-full:FinanceIncomeCost", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6017": { "value": "-288806000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6020": { "value": "-296735000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLossBeforeTax", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6028": { "value": "-384000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6031": { "value": "-254000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncomeTaxExpenseContinuingOperations", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6037": { "value": "-288422000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6040": { "value": "-296481000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6046": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6049": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6055": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6058": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6065": { "value": "-288422000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6068": { "value": "-296481000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6075": { "value": "-3.99", "decimals": 2, "dimensions": { "concept": "ifrs-full:BasicEarningsLossPerShare", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK/xbrli:shares" } }, "f6076": { "value": "-3.99", "decimals": 2, "dimensions": { "concept": "ifrs-full:DilutedEarningsLossPerShare", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK/xbrli:shares" } }, "f6079": { "value": "-4.25", "decimals": 2, "dimensions": { "concept": "ifrs-full:BasicEarningsLossPerShare", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK/xbrli:shares" } }, "f6080": { "value": "-4.25", "decimals": 2, "dimensions": { "concept": "ifrs-full:DilutedEarningsLossPerShare", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK/xbrli:shares" } }, "f6100": { "value": "-290725000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6103": { "value": "-294818000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLossFromOperatingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6110": { "value": "10560000", "decimals": -3, "dimensions": { "concept": "ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6113": { "value": "2099000", "decimals": -3, "dimensions": { "concept": "ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6118": { "value": "1194000", "decimals": -3, "dimensions": { "concept": "ifrs-full:InterestReceivedClassifiedAsOperatingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6121": { "value": "483000", "decimals": -3, "dimensions": { "concept": "ifrs-full:InterestReceivedClassifiedAsOperatingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6126": { "value": "8000", "decimals": -3, "dimensions": { "concept": "ifrs-full:InterestPaidClassifiedAsOperatingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6129": { "value": "8000", "decimals": -3, "dimensions": { "concept": "ifrs-full:InterestPaidClassifiedAsOperatingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6135": { "value": "-278979000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6138": { "value": "-292244000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6144": { "value": "-1598000", "decimals": -3, "dimensions": { "concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6147": { "value": "-340000", "decimals": -3, "dimensions": { "concept": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6152": { "value": "-19342000", "decimals": -3, "dimensions": { "concept": "ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6155": { "value": "27413000", "decimals": -3, "dimensions": { "concept": "ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6160": { "value": "-299919000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6163": { "value": "-265171000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInOperatingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6171": { "value": "3000000", "decimals": -3, "dimensions": { "concept": "ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6174": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6181": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6184": { "value": "77000000", "decimals": -3, "dimensions": { "concept": "ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6191": { "value": "77000000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6194": { "value": "70000000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6198": { "value": "74000000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6201": { "value": "-7000000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInInvestingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6207": { "value": "252000", "decimals": -3, "dimensions": { "concept": "ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6210": { "value": "239000", "decimals": -3, "dimensions": { "concept": "ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6215": { "value": "200000000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProceedsFromIssuingShares", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6218": { "value": "336000000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProceedsFromIssuingShares", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6223": { "value": "12708000", "decimals": -3, "dimensions": { "concept": "ifrs-full:PaymentsForShareIssueCosts", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6226": { "value": "17578000", "decimals": -3, "dimensions": { "concept": "ifrs-full:PaymentsForShareIssueCosts", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6230": { "value": "187040000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6233": { "value": "318183000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashFlowsFromUsedInFinancingActivities", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6237": { "value": "-38879000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6240": { "value": "46012000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6244": { "value": "294199000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6247": { "value": "248618000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6255": { "value": "1483000", "decimals": -3, "dimensions": { "concept": "ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6258": { "value": "-431000", "decimals": -3, "dimensions": { "concept": "ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6264": { "value": "256803000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6267": { "value": "294199000", "decimals": -3, "dimensions": { "concept": "ifrs-full:CashAndCashEquivalents", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6286": { "value": "30209000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6289": { "value": "702053000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6292": { "value": "-377749000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6295": { "value": "354513000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6300": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6303": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6306": { "value": "-296481000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6309": { "value": "-296481000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6314": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6317": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6320": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6323": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6329": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6332": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6335": { "value": "-296481000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6338": { "value": "-296481000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6345": { "value": "5671000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IssueOfEquity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6348": { "value": "333329000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IssueOfEquity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6351": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:IssueOfEquity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6354": { "value": "339000000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IssueOfEquity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6359": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ShareIssueRelatedCost", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6362": { "value": "17578000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ShareIssueRelatedCost", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6365": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ShareIssueRelatedCost", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6368": { "value": "17578000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ShareIssueRelatedCost", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6373": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughExerciseOfOptions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6376": { "value": "3862000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughExerciseOfOptions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6379": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughExerciseOfOptions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6382": { "value": "3862000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughExerciseOfOptions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6388": { "value": "5671000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6391": { "value": "319613000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6394": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6397": { "value": "325284000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners", "entity": "scheme:549300KTNBPTZLF01130", "period": "2021-01-01T00:00:00/2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6401": { "value": "35880000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6404": { "value": "1021666000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6407": { "value": "-674230000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6410": { "value": "383316000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6414": { "value": "35880000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6417": { "value": "1021666000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6420": { "value": "-674230000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6423": { "value": "383316000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6428": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6431": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6434": { "value": "-288422000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6437": { "value": "-288422000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ProfitLoss", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6442": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6445": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6448": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6451": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:OtherComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6457": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6460": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6463": { "value": "-288422000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6466": { "value": "-288422000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ComprehensiveIncome", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6473": { "value": "5044000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IssueOfEquity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6476": { "value": "197956000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IssueOfEquity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6479": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:IssueOfEquity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6482": { "value": "203000000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IssueOfEquity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6487": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ShareIssueRelatedCost", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6490": { "value": "12708000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ShareIssueRelatedCost", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6493": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:ShareIssueRelatedCost", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6496": { "value": "12708000", "decimals": -3, "dimensions": { "concept": "ifrs-full:ShareIssueRelatedCost", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6501": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughExerciseOfOptions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6504": { "value": "3897000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughExerciseOfOptions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6507": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughExerciseOfOptions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6510": { "value": "3897000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughExerciseOfOptions", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6516": { "value": "5044000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6519": { "value": "189145000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6522": { "value": "0", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6525": { "value": "194189000", "decimals": -3, "dimensions": { "concept": "ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "f6529": { "value": "40924000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:IssuedCapitalMember", "unit": "iso4217:SEK" } }, "f6533": { "value": "1210811000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:AdditionalPaidinCapitalMember", "unit": "iso4217:SEK" } }, "f6536": { "value": "-962652000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "ifrs-full:ComponentsOfEquityAxis": "ifrs-full:RetainedEarningsMember", "unit": "iso4217:SEK" } }, "f6539": { "value": "289083000", "decimals": -3, "dimensions": { "concept": "ifrs-full:Equity", "entity": "scheme:549300KTNBPTZLF01130", "period": "2023-01-01T00:00:00", "unit": "iso4217:SEK" } }, "pp-value-31-1": { "value": "Note 1 Accounting principlesVicore\u2019s consolidated accounts have been preparedin accordance with the International Financial Reporting Standards (IFRS) issued by the Interna-tional Accounting Standards Board (IASB) as well as the interpretations from the IFRS Interpretation Committee (IFRS IC) as adopted by the European Union (EU). Furthermore, the group also applies theAnnual Accounts Act (1995: 1554) and the SwedishFinancial Reporting Board\u2019s recommendation RFR 1 \u201dSupplementary Accounting Rules for Groups\u201d. Preparing financial statements in accordance with IFRS requires the company management to make estimates for accounting purposes. These assessments and estimates are based on historical experiences, as well as other factors that are considered to be reasonable during the current circumstances. The actual result can deviate from these estimates and assessments.instruments or debt instruments, which arise are reported directly in the profit/loss for the year. For business combinations where the transferred remuneration exceeds the fair value of acquired assets and assumed liabilities that are reported separately, the difference is reported as goodwill. When the difference is negative, a so-called bargainpurchase, this is reported directly in the profit/loss for the year.When acquiring an asset, the acquisition value is allocated to the individual identifiable assets and the debts, based on their relative fair values. Such a transaction does not give rise to goodwill.Eliminated transactions during consolidationIntra-group receivables and liabilities, income or expenses and unrealised gains or losses which arise from intra-group transactions between group companies are eliminated in the preparation of the consolidated accounts. Unrealised gains arising from transactions with associated companies are eliminated to the extent which corresponds to the group\u2019s ownership in the company. Unrealised losses are eliminated in the same way, but only to the extent that there is no impairment of the asset.CurrencyFunctional currency and reporting currencyFunctional currency is the currency in the primary economic environments in which the companies operate. The parent company\u2019s functional currency is the Swedish kronor, which is also the reporting currency for the parent company and the group. Unless otherwise stated, all amounts are rounded to the nearest thousand (KSEK).Subsidiaries are all the companies over which Vicorehas a controlling influence. The group controls acompany when it is exposed to, or has rights to, var-iable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Subsidiaries are included inthe consolidated accounts as of the date on which the controlling influence is transferred to the group. They are excluded from the consolidated accounts asof the date on which the controlling influence ceases.Subsidiaries are reported according to the acqui-sition method. The method implies that acquiring a subsidiary is considered a transaction, wherebythe group indirectly acquires the subsidiary\u2019s assets and liabilities. In the acquisition analysis, the fair value of acquired identifiable assets and assumed liabilities, as well as any holdings without controlling influence, is determined on the acquisition date. Transaction costs, excluding transaction costs attributable to the issue of equity Foreign currency transactionsTransactions in foreign currency are translated to the functional currency at the exchange rate as on the transaction date. Monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rate on the balance sheet date. Exchangerate differences that arise are recognized in the profit/loss for the year. Exchange gains and exchange losses on operating receivables and operating liabilities are reported in operating results, while exchange gains and exchange losses on financial receivables and liabilities are reported as financial items.perating segmentsOperating segments are reported in a way that corresponds with internal reporting structures. The profit/loss generated by a business segment is then followed up by the company\u2019s chief operating decision maker, who is responsible for assessing the profit/loss figures and allocating resources to the business segment. In the group, this function is identified as the company\u2019s CEO.An operating segment is a component of the group that engages in business activities from which it may earn revenues and incur expenses, and for which discrete financial information is available. Vicore does not divide its business into different segments, instead it sees the entire business of the group as one segment. This followsthe company\u2019s internal organization and reporting structures.Revenue from contracts with customersThe group reports revenue when the group fulfils a performance obligation, i.e. when a promised prod-uct is delivered to the customer and the customer takes control of the product. Control of a perfor-mance obligation can be transferred over time or ata point in time. Revenue consists of the amount thecompany expects to receive as compensation for the transferred products or services. For the group to report revenue from contracts with customers, each customer contract is analyzed according to the five-step model included in the standard:Step 1: Identify a contract between at least two parties that consists of enforceable rights and obligations.Step 2: Identify the performance obligations in the contract.Step 3: Determine the transaction price, i.e. the amount of consideration that the company is expected to receive in exchange for the promised goods or services.Step 4: Allocate the transaction price over the identified performance obligations.Step 5: Recognize revenue when the performance obligations are satisfied, i.e. when control is transferred to the customer.The group\u2019s net sales are currently not a significant part of the business.Government grantsGovernment grants are reported in the statement of financial position and the statement of comprehensive income when there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received. The grant is recognised as incomeover the period necessary to match them with Pension obligationsThe group only has defined contribution pension plans. In defined contribution plans, the group pays fixed contributions to a separate entity and has no legal or constructive obligation to pay further contributions if this entity does not have sufficient assets to pay all the remuneration to employees connected with the employees\u2019 service during the current or prior periods. Therefore, the group has no additional risk. For the group\u2019s obligations regarding contributions for defined contribution plans, these are reported as an expense in the consolidated profit/loss as the benefits are earned.Incentive programsThere are four types of share-based incentive programs in the group: two option programs for employees, and two share awards programs for certain board members. The option and share awards have been granted free of charge and are settled with equity instruments.The fair value of share-based payments is accounted for as personnel costs. The fair value of the employee stock options is determined at grant date with the Black-Scholes model for pricing of options. For the share awards, the fair value is determined at the time of allocation using a Monte Carlo simulation of future stock price development.The cost is reported, along with a corresponding increase in equity, during the period in which the vesting conditions are fulfilled, up to and including the date when the persons concerned are fully entitled to the compensation.The accumulated cost included in each reporting period shows to what extent the vesting period has been recognised with an estimate of the number of share-related instruments that eventually will be vested.Social security contributions attributable to share-related instruments to employees as compensation for purchased services must be expensed over the periods during which the services are performed. This cost must then be calculated using the same valuation model that was used whenthe related costs, for which they are intended tocompensate, on a systematic basis.Leasing agreementThe group\u2019s leasing portfolio consists of a fewoperating leases for premises, which are the two classes of leased assets presented by the group.The leasing agreements are reported as contract assets with a corresponding lease liability on the daythat the leased asset is available for use by the group.Short-term leases and low value leases are excluded.Each leasing payment is divided between amortiza-tion of the lease debt and financial cost. The financialcost shall be distributed over the lease period so thateach accounting period is charged with an amount corresponding to a fixed interest rate for the liabilityreported during each period.The leasing period is determined as the non-cancel-lable period together with both periods covered by an option to extend the lease if the lessee is reasonablysure to take advantage of that option, and periods covered by an opportunity to terminate the lease if thelessee is reasonably sure not to exercise that option.The group's leasing liabilities are recognized at the present value of the group's future leasing fees. Leasing payments have been discounted with thegroup's marginal loan interest rate.The group's contract assets are recognized at cost and initially include the present value of theleasing liabilities, adjusted for leasing fees paid onor before the commencement date and initial directexpenses. Recovery costs are included in the asset ifa corresponding provision regarding recovery costs has been identified. The contract asset is amortizedon a straight-line basis over the shorter of the asset'suseful life and the duration of the lease.Employee benefitsShort-term remunerationShort-term remuneration to employees, such as salary, social security contributions, holiday pay and bonus, is expensed when the employees perform the services.the options were issued. The provision made shall be reassessed at each reporting date based on a calculation of the amount social charges that may be payable when the instruments are settled.Financial incomeFinancial income consists of capital gains on and dividend incomes from financial fixed assets. Dividend income is recognized when the right to receive a dividend has been established.Exchange rate gains and losses are reported net.Financial costsFinancial costs consist mainly of interest expenseson loans. Exchange rate gains and losses are reported net.Income taxesIncome taxes consist of current tax and deferred tax. Income taxes are recognized in profit or loss for the year, except when the underlying transac-tion is recognized in other comprehensive incomeor equity, in which case the tax effect is recognized in other comprehensive income or equity.Current taxCurrent tax is the tax that must be paid or received for the current year, with the application of the tax rates that have been decided, or in practice decided, on the balance sheet date. Current tax also includes adjustments to the current tax attributable to previous periods.Earnings per shareEarnings per share before dilution are calculated as profit or loss attributable to the parent company shareholders divided by the weighted average number of ordinary shares outstanding during the period.Earnings per share after dilution are calculated as profit or loss attributable to the parent company shareholders divided, in some cases adjusted, by the sum of the weighted average number of ordinary shares and potential ordinary shares that may give rise to dilution effects. A dilution effect of potential ordinary shares is recognized only if a translation into ordinary shares would lead to a reduction of earnings per share after dilution.Acquired intangible assetsIntangible assets in the group consist of patents, licenses and similar rights. They are valued at cost that is decreased by accumulated depreciation andany accumulated impairment losses.An intangible asset is recognized if it is probable that the asset will generate future economic benefits for the group, the criteria for capitalization are met and the costs can be measured reliably. An intangible asset is valued at cost when it is includedfor the first time in the financial report. Intangible assets with finite useful lives are reported at cost less depreciation and any impairment losses. Intangible fixed assets with finite useful lives are depreciated linearly over the asset\u2019s estimated useful life. Intangible assets with indefinite useful lives are instead tested annually for impairment.Intangible assets with finite and indefinite useful lives are reviewed for impairment requirements in cases where there are indications that a write-down may be needed. The useful life of intangible assets is reviewed at each balance sheet date and adjusted if necessary.Capitalization of development expenditureThe expenses that arise during the development phase are capitalized as intangible assets when, according to management\u2019s assessment, they are likely to result in future economic benefits for the group, the criteria for capitalization are met and the costs can be measured in a reliable way. Otherwise,development expenses are expensed as normal operating expenses.The group only has acquired intangible assets.Depreciation principlesDepreciation begins when the asset can be used, i.e. when it is in the place and in the condition required to be able to use it in the way managementintends. The estimated useful life for intangible fixed assets with a finite useful life is 5 years. Depre-ciation is made on a straight-line basis over theestimated useful life of the asset, which coincides with the remaining patent period for the product. Tangible fixed assetsTangible fixed assets are reported in the group at cost after deductions for accumulated deprecia-tion and any accumulated impairment losses. The cost includes the purchase price and any costs directly attributable to the asset to bring it in place and in condition to be utilized in accordance with the purpose of the acquisition.The carrying amount of an asset is derecognized from the balance sheet when disposing or divesting, or when no future economic benefits are expected from use or disposing/divesting of the asset. Gains or losses arising from the sale or disposal of an asset consist of the difference between the selling price and the asset\u2019s carrying amount with the deduction of direct sales costs. Gains and losses are reported as other operating income/expenses.Additional expensesAdditional expenses are added to the asset\u2019s carrying amount only if it is probable that the future economic benefits associated with the asset will be leveraged by the group and that the cost of the asset can be measured reliably. All other additional expenses are reported as an expense during the period they arise. Repairs are expensed on an ongoing basis.Depreciation principlesThe depreciable amount shall be allocated on a systematic basis over the asset\u2019s estimated useful life. Used depreciation methods, residual values and useful lives are reviewed at the end of each year.The estimated useful lives are:Equipment ...............................5 yearsImpairment of non-financial assetsThe group\u2019s reported assets are assessed in cases where there are indications of a decline in value of tangible or intangible assets, i.e. whenever events or changes in circumstances indicate that the fair value is not recoverable. Furthermore, the group\u2019s development projects are reviewed annually for impairment requirements until they are available for use. This is done regardless of whether there are indications of a decline in value or not.An impairment is recognized when an asset\u2019s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of the asset\u2019s fair value less the cost of sale on the one hand and the value in use on the other. When assessing impairment, assets are grouped at the lowest level where there are separate identifiable cashflows (cash-generating units). When the need for impairment has been identified for a cash-gener-ating unit (group of units), the impairment amount is distributed proportionally among the assets included in the cash-generating unit (group of units).A previously recognized impairment is reversed if the recovery amount is deemed to exceed thefair value. Reversal does not occur with an amount that is greater than what the fair value would have been recorded to if the impairment had not been recognized in previous periods. Any reversals arereported in the income statement.Financial assets and liabilitiesA financial asset or financial liability is recognized in the balance sheet when the group becomes a party according to the instrument\u2019s contractualterms. A financial asset is removed from thebalance sheet when the rights in the agreement are realized, expire or when the group loses control over them. The same applies to a part of a financial asset. A financial liability is removed from the balance sheet when the obligation in the agreement is fulfilled or otherwise extinguished. The same applies to a part of a financial debt.Acquisitions and divestments of financial assets are reported on the trade date. The trade date constitutes the day when the company undertakes to acquire or divest the asset.Financial instruments are classified on initial recognition, including on the basis of what purpose the instrument was acquired and man-aged. This classification determines the valuation Classification and valuation of financial assetsThe classification of financial assets that are debt instruments, is based on the group\u2019s business model for managing the asset and the nature of theasset\u2019s contractual cash flows.Assets are classified according to:Amortized costFair value through profit or loss, orFair value through other comprehensive incomeThe group\u2019s financial assets that are classified at amortized cost include accounts receivable, certain other receivables, short-term investments, and cash and cash equivalents. Financial assets classified at amortised cost are initially measured at fair value with the addition of transaction costs. After initial recognition, the assets are valued at amortized cost after a deduction of a loss reserve for expected credit losses. Assets classified at amortized cost are held according to the business model to collect contractual cash flows, which are solely payments of principal and interest on the outstanding principal amount.The group\u2019s financial assets that are classified at fair value through profit or loss relate to holdings in listed and non-listed shares.Impairment of financial assetsThe group\u2019s impairment model is based on expected credit losses, and takes into account prospective information. A loss reserve is made when there is an exposure to credit risk, usually at initial recognition for an asset or receivable. Classification and valuation of financial liabilitiesThe group\u2019s financial liabilities consist of accounts payable and other current liabilities, which are allclassified at amortized cost. Financial liabilities recognized at amortized cost are initially measuredat fair value including transaction costs. After the initial recognition, they are valued according to the effective interest method.Cash and cash equivalentsCash and cash equivalents consist of cash and balances as well as immediately available credit balances with banks and corresponding financial institutions.EquityAll shares in the company are ordinary shares, which are reported as equity. The share capital is reported up to its quota value and any excess part is reported as Other contributed capital. Transaction costs, directly attributable to the issue of new ordinary shares or options, are reported, net after tax, in equity as a deduction from the issue proceeds.Contingent liabilitiesA contingent liability is recognised when there is a possible commitment that arises from past events and whose existence is confirmed only by one or more uncertain future events, or when there is a commitment that is not reported as a liability or provision due to it being unlikely that an outflow of resources will be required.Cash flowCash and cash equivalents consist of available cash, bank credit balances and other liquid investments with an original maturity of less than three months, which are exposed to insignificant value fluctuation. Incoming and outgoing payments are reported in the cash flow statement. The cash flow statement has been prepared in accordance with the indirect method.Note 2 Judgements and accounting estimatesThe preparation of the financial statements in accordance with IFRS requires company man-agement to make judgements and accounting estimates that affect the application of the accounting policies and the carrying amounts of assets, liabilities, revenue and expenses. The actualoutcome could deviate from these estimates.The accounting estimates and assumptions are evaluated continuously. Changes to the accounting estimates are recognized in the period in which the change is made if the change only has affected the period, or in the period in which the change is made and future periods if the change affects both the current period and future periods.Sources of uncertainty in the accounting estimatesThe sources of uncertainty in the accounting estimates, entailing a significant risk that the value of assets or liabilities might need to be adjusted to a material extent during the forthcoming fiscal year,include impairment testing of intangible assets with indefinite useful lives.Impairment testing of intangible assetsWhen impairment testing intangible assets, a num-ber of significant assumptions and judgements must be taken into account in order to calculate a recoverable amount. These assumptions and judgements relate to, among others, future expected selling price for the company\u2019s products C21, IMiD and C106, expected market penetration, expected development-, sales and marketing costs and expected likelihood that the products will pass the remaining stages of development. The assumptions are based on industry- and market-specific data and are produced by the man-agement and reviewed by the Board of Directors. For more information about impairment testing, see Note 15 \"Patent, licenses and similar rights\".Other judgments and accounting estimatesCapitalization of intangible assetsDevelopment expenditures are capitalized when they fulfill the criteria set out in IAS 38 and are expected to represent material amounts for the development initiative as a whole. Development expenditures are otherwise expensed as normal operating costs. The most important criteria for capitalization are that the end product of the development work has a demonstrable future earning capacity or cost savings and cash flow, andthat there are technical and financial preconditions to finish the development work when it begins. The group only has acquired intangible assets. Since regulatory approval has not yet been obtained, no costs have been capitalized.Research and development expenses The company conducts research and developmentwith external collaboration partners, such as clinical research organizations (CROs). The company estimate the timing of the costs when the project commences. This cost is then used as abasis for settlement with the external collaboration partner. An evaluation and update of the calculationis performed monthly and forms the basis for booking accrued costs attributable to research and development.Incentive programsThe group has four active share-based long-termincentive programs. The applicable accounting poli-cies are described in Note 1 \"Accounting principles\". The cost for the remuneration that is recognized in a period is dependent on the original valuation that was made on the contract date of with the holder of the option/share award, the number of months of service required by the participant for becoming entitled to options (accruals are made over thisperiod), the number of options that are expected to be vested by the participant under the terms of the programs and a continuous reassessment of the value of the tax benefits for the participants in the incentive programs (for determining provisions for social security contributions). Those estimates which affect the cost in a period and the corre-sponding increase in equity mainly refer to inputs for the valuation of the options. The models used for this purpose are the Black & Scholes model and a Monte Carlo simulation. Significant assumptions in these valuations are described in Note 8 \"Share-based payments\".Tax loss carryforwardsThe group\u2019s tax loss carryforwards have not been measured and are not recognized as a deferred tax asset. These tax loss carryforwards will be measured valued only when the group has established a level of earnings which management with confidence estimate will lead to taxable profits.Not 3 Operating segmentsVicore does not divide its business into different operating segments. Instead the group\u2019s entire business is treated as one operating segment. This reflects the company\u2019s internal organisation and reporting sys-tem. Vicore\u2019s chief operating decision maker is the CEO. Currently, Vicore is operating mainly in Sweden, where the group\u2019s tangible and intangible fixed assets are attributed.Note 4 Operating expenses by nature of expenseThe total expenses classified by function are distributed in the following cost categories:2022 2021Other external expenses 224,713 256,517Personnel expenses 59,169 33,304Depreciation and amortization 3,612 3,598Other operating expenses 4,784 2,492Total 292,278 295,911Note 5 Audit feesErnst & Young AB 2022 2021Audit fees* 435 450Other audit related services 170 92Tax consultancy services 0 0Other services 0 10Total 605 552* Audit engagement refers to fees for the statutory audit, i.e. work that has been necessary to produce the auditor\u2019s report as well as audit advisory services provided in connection with the audit engagement.Note 6 Leases 2022 2021 Dec 31Dec 31Contract assetsPremises 63 317Total 63 317Contract liabilitiesLong-term 0 320Short-term 65 0Total 65 320The following amounts related to leasing contracts are reported 2022 2021 in the consolidated statement of comprehensive income:Leasing fees, short-term 1,184 1,066DepreciationPremises 255 239Interest 4 6Total 1,443 1,311The total cash flow related to leasing agreements was 259 KSEK (245 KSEK) for 2022. For information on the maturity of leases, see Note 19 \"Financial risks\".Note 7 Employees and personnel costsAverage number of 2022 2021employeesNo. of of which men/ No. of of which men/ employeeswomenemployeeswomenParent company 5 60%/40% 4 50%/50%Subsidiaries 16 19%/81% 12 30%/70%Group total 21 29%/71% 16 36%/64%Personnel costs for the Board of Directors, senior executives and other employees 2022 2021GroupThe Board and other senior executivesSalaries and other remuneration 25,393 17,898Social security contributions 6,336 -120Pension costs 4,527 3,04636,256 20,824GroupOther employeesSalaries and other remuneration 15,406 9,048Social security contributions 3,529 744Pension costs 2,181 2,23921,116 12,031GroupOther personnel costs 1,797 4491,797 449Total personnel costs 59,169 33,304Parent companyThe Board and other senior executivesSalaries and other remuneration 12,063 9,813Social security contributions 3,339 -2,154Pension costs 2,210 1,50817,612 9,167Parent companyOther employeesSalaries and other remuneration 874 906Social security contributions 262 277Pension costs 143 721,279 1,255Parent companyOther personnel costs 779 226779 226Total personnel costs 19,670 10,648Senior executives include members of the Board of Directors, the CEO and other senior executives.Salaries and other remunerationCosts related to the long-term incentive programs amounts to 3,897 KSEK (3,862 KSEK) of the payroll expenses and 975 KSEK (-5,425 KSEK) of the social security contributions. PensionsAll pension plans in the group are defined contribution plans. The group\u2019s total cost for defined contribution plans amounted to 6,709 KSEK (5,285 KSEK). Gender breakdown among senior executives2022\ue878 2021\ue878 Dec 31Dec 31GroupProportion of women on the Board 40% 33%Proportion of men on the Board 60% 67%Proportion of women among other senior executives 50% 50%Proportion of men among other senior executives 50% 50%Parent companyProportion of women among other senior executives 25% 25%Proportion of men among other senior executives 75% 75%Information regarding remuneration to the Board and other senior executivesBasic Share- Other salary, Pension Variable based remunera-2022board fee*costsremunerationpaymentstion* TotalChairman of the BoardJacob Gunterberg 438 0 0 0 637 1,075Members of the BoardHans Schikan 175 0 0 91 275 541Maarten Kraan 175 0 0 91 275 541Sara Malcus 175 0 0 91 275 541Heidi Hunter 175 0 0 170 275 620Senior executivesCEO 2,738 809 821 613 0 4,981Other senior executives** 13,326 3,718 3,263 2,597 0 22,904Total 17,202 4,527 4,084 3,653 1,737 31,203* Board fees as resolved at the AGM, excluding social security contributions and remuneration of board committee work for the May 2022 to May 2023 financial year. Other remuneration include remuneration for board committee work. Other remuneration also includes the additional board fee decided by the general meeting, which was conditional on the acquisition of shares in the company. ** For more information, see \"Remuneration for senior executives\" below.Basic Share- Other salary, Pension Variable based remunera-2021board fee*costsremunerationpaymentstion* TotalChairman of the BoardMichael Wolff Jensen 450 0 0 730 50 1,230Members of the BoardJacob Gunterberg 150 0 0 0 125 275Hans Schikan 150 0 0 142 50 342Maarten Kraan 150 0 0 142 75 367Sara Malcus 150 0 0 108 50 308Heidi Hunter 150 0 0 365 50 565Senior executivesCEO 2,753 745 261 431 0 4,190Other senior executives** 9,484 2,301 753 1,287 0 13,825Total 13,437 3,046 1,014 3,205 400 21,102* Board fees as resolved at the AGM, excluding social security contributions and remuneration of board committee work for the May 2021 to May 2022 financial year. Other remuneration include remuneration for board committee work. ** For more information, see \"Remuneration for senior executives\" below.Share-based paymentsShare-based payments refer to share awards and options granted to independent directors, the CEO, other senior executives, and other employees. Each vested share award entitles the holder to receive one share in the company, provided that the holder is still a member of the Board of Directors of the company at the relevant time of vesting. Each option entitles the holder to acquire one share in the company for a predetermined exercise price. The options are subject to vesting over a three year period whereby all options shall be vested on the third anniversary of the granting date, provided that the holder, with some customary exceptions is still employed by the company. The participants in the programs have received the share awards / options free of charge. For further information about the incentive programs, see Note 8 \"Share-based payments\".Other remunerationOther remuneration include remuneration for board committee work. For the fiscal year 2022, other remu-neration also includes the additional board fee decided by the general meeting, which was conditional on the acquisition of shares in the company. Remuneration for senior executivesRemuneration of the CEO and other senior executives consists of, in accordance with the guidelines for remuneration decided by the shareholder's meeting in 2021, basic salary, pension benefits, bonus and share-based incentives adopted by the shareholders\u2019 meeting (e.g. employee stock options). Other senior executives refer to the individuals who, together with the CEO, constitute the group management. As of January 1, 2021, other senior executives refer to the Chief Financial Officer, Chief Medical Officer, Chief Scientific Officer, VP Clinical Development, Program Director, early development, and Chief Administrative Officer. During 2021, the group of other senior executives was expanded as follows: Head of Digital Therapeutics (July 1, 2021), Chief Commercial Officer (October 2, 2021) and Head of Business Develop-ment (November 8, 2021).The CEO has a period of notice of six months in the event the termination is made by the group or if the CEO resigns. Other senior executives have a period of notice of three to six months, in the event the termination is made by the group or if the senior executive resigns.In addition to salary during the termination period, the CEO is entitled to a termination benefit corresponding of six months\u2019 salary in the event of termination by the company on a basis other than a breach of contract.Note 8 Share-based paymentsThe purpose of share-based incentive programs is to promote the company\u2019s long-term interests by motivating and rewarding the company\u2019s senior management and other co-workers in line with the interests of the shareholders. As of December 31, 2022, Vicore has four active incentive programs that include the management team, other employees and certain board members. Assuming full utilization and maximum goal achievement of all granted employee stock options and share awards as of December 31, 2022, corresponding to 2,988,489 shares, would entail a dilution of 3.5 percent. Taking into account also non-granted employee stock options and warrants that may be used as hedge for social security contributions, the maximum dilution as of December 31, 2022, amounts to 5.6 percent.Long-term incentive program 2018The Extra General Meeting in Vicore held on August 13, 2018, resolved, in accordance with the Board of Directors\u2019 proposal, to adopt a long-term incentive program for certain of the company\u2019s senior manage-ment and key persons (\u201cCo-worker LTIP 2018\u201d) in Vicore. A maximum of 2,000,000 options (Co-worker LTIP 2018) may be allotted to participants under the program. Of these, a total of 1,325,800 options and 475,000 share awards have been allocated. The increase in the company\u2019s share capital in full utilization of the incentive program amounts to a maximum of approximately SEK 1,000,000, corresponding to a dilution of approximately 2.4 percent of the total number of shares. The options have been granted to the participants of the incentive programs free of charge and the settlement is made with equity instruments.Co-worker LTIP 2018Co-worker LTIP 2018 is an incentive program intended for members of senior management and key persons in the company. According to the program participants will be granted, free of charge, options subject to three year vesting that entitle to acquire a maximum of 2,000,000 shares in the company in total, in accordance with the terms stipulated below.The Board of Directors of the company believes that an equity-based incentive program is a central part of an attractive and competitive remuneration package in order to attract, retain and motivate competent mem-bers of senior management and key persons in the company, and to focus the participants on delivering exceptional performance which contributes to value creation for all shareholders.Co-worker LTIP 2018 is an incentive program under which the participants will be granted options free of charge. The Board of Directors shall resolve upon the allocation of options annually or at such time as the Board of Directors can be considered as relevant to such decision (with each respective date of granting being a \u201cgranting date\u201d). Each option entitles the holder to acquire one share in the company for a predetermined exercise price. The exercise price per share shall correspond to 150 percent of the volume weighted average price of the company\u2019s share for the five trading days preceding the granting date. The options are subject to vesting over a three year period whereby all options shall be vested on the third anniversary of the granting date, provided that the holder, with some customary exceptions is still employed by the company. The latest point in time at which vested options may be exercised shall be the fourth anniversary of the granting date.The options are valued according to the so-called Black & Scholes model, which means that the value of the options depends, among other things, on the value of the underlying share, the options\u2019s issue price and life, risk-free interest rate and volatility. The volatility has been based on the expected volatility of the Vicore share and other listed companies with similar operations. The risk-free interest rate was equated with the interest rate for Swedish govern-ment bonds. The fair value of the options at the time of allocation during 2020 amounts to SEK 3.98 per option. No allocation within Co-worker LTIP 2018 has taken place in 2021 or 2022. For further information about inputs that have been used in the model, see the Annual Reports for the years 2018-2021.Long-term incentive program 2020The Annual General Meeting in Vicore Pharma Holding AB held on May 20, 2020, resolved, in accordance with the proposal from the Nomination Committee, to adopt a long-term incentive program for the new members of the Board of Directors (\u201cBoard LTIP 2020\u201d) in Vicore Pharma Holding AB. A maximum of 525,000 share awards may be allotted to participants in the program Board LTIP 2020. The increase in the company\u2019s share capital, assuming full utilization, amounts to a maximum of approximately SEK 262,500, corresponding to a dilution of 0.6% of the total number of shares.Board LTIP 2020Board LTIP 2020 is a program under which the participants will be granted, free of charge, share awards subject to performance vesting (\u201cshare awards\u201d) that entitle to shares in the company to be calculated in accordance with the principles stipulated below, however a maximum of 525,000 shares. Board LTIP 2020 is intended for the newly elected, main owner independent, members of the Board of Directors in the company. The Nomi-nation Committee believes that an equity-based incentive program is a central part of a competitive remuneration package in order to attract, retain and motivate internationally competent members of the Board of Directors, and to focus the partici-pants on delivering exceptional performance which contributes to value creation for all shareholders.The share awards shall vest gradually over approximately three years, corresponding to three terms up to the date of, whichever is earliest, (i) the Annual General Meeting 2023 or (ii) June 1, 2023 (\u201dvesting date\u201d), where each term equals the period from one Annual General Meeting up until the day falling immediately prior to the next Annual General Meeting or the vesting date, as applicable (each such period a \u201cterm\u201d). The share awards shall vest by 1/3 at the end of each term, provided that the participant is still a member of the Board of Directors of the company on said date. In addition to the vesting conditions just stated, the share awards are subject to performance vesting based on the development of the company\u2019s share price, in accordance with the vesting conditions below.The share awards are subject to performance vesting based on the development of the compa-ny\u2019s share price over the period from the date the share awards are allocated (\u201dgrant date\u201d) up to and including the vesting date. The development of the share price will be measured based on the volume weighted average price of the company\u2019s share on Nasdaq Stockholm for the 30 trading days immediately following the grant date and the 30 trading days immediately preceding the vesting date, respectively. In the event the price of the com-pany\u2019s share has thereby increased by more than 150 percent, 100 percent of the share awards shall vest, and should the share price have increased by 50 percent, 25 percent of the share awards shall vest. In the event of an increase of the share price between 50 and 150 percent, vesting of the share awards will occur linearly. Should the increase of the share price be less than 50 percent, no vesting will occur. The earliest point in time at which vested share awards may be exercised shall be the day falling immediately after the vesting date.The valuation of the share awards is based on a Monte Carlo simulation in accordance with accepted valuation theory. Volatility has been based on the expected volatility of the Vicore share and other listed companies with similar operations. The risk-free interest rate has been derived through an interpolation between a 2-year and 5-year government bond, respectively. The fair value of the share awards at the time of allocation amounts to SEK 5.18 per share award. In order to calculate the value of the share awards in relation to the current performance conditions, a starting value is used that corresponds to the volume-weighted average price paid for the Vicore share over a fixed period, which in this case corresponds to the value of the underlying share at the time of valuation.Long-term incentive programs 2021 The Annual General Meeting in Vicore Pharma Holding AB held on May 11, 2021, resolved to implement a long-term incentive program for sen-ior management and key persons in the company (\u201cCo-worker LTIP 2021\u201d) and to implement a long-term performance-based incentive program for independent board members in the company who are not participants in Board LTIP 2020 (\u201cBoard LTIP 2021\u201d). A maximum of 3,000,000 options (Co-worker LTIP 2021) and 61,773 share awards (Board LTIP 2021) may be allotted to participants in the programs. The increase in the company\u2019s share capital, assuming full utilization of both incentive programs, amounts to a maximum of approximately SEK 1,530,887, corresponding to a dilution of approximately 3.6 percent of the total number of shares.Board LTIP 2021Board LTIP 2021 is a program under which the participants will be granted, free of charge, share awards subject to performance vesting that entitle to shares in the company to be calculated in accordance with the principles stipulated below, however a maximum of 61,773 shares. Board LTIP 2021 is intended for independent board members in the company who are not participants in Board LTIP 2020. The Nomination Committee believes that an equity-based incentive program is a central part of a competitive remuneration package in order to attract, retain and motivate internationally competent members of the Board of Directors, and to focus the partici-pants on delivering exceptional performance which contributes to value creation for all shareholders.The share awards shall vest gradually over approximately three years, corresponding to three terms up to the date of, whichever is earliest, (i) the Annual General Meeting 2024 or (ii) June 1, 2024 (\u201dvesting date\u201d), where each term equals the period from one Annual General Meeting up until the day falling immediately prior to the next Annual General Meeting or the vesting date, as applicable (each such period a \u201cterm\u201d). The share awards shall vest by 1/3 at the end of each term, provided that the participant is still a member of the Board of Directors of the company on said date. In addition to the vesting conditions just stated, the share awards are subject to performance vesting based on the development of the company\u2019s share price, in accordance with the vesting conditions below.The share awards are subject to performance vesting based on the development of the compa-ny\u2019s share price over the period from the date the share awards are allocated (\u201dgrant date\u201d) up to and including the vesting date. The development of the share price will be measured based on the volume weighted average price of the company\u2019s share on Nasdaq Stockholm for the 30 trading days immediately following the grant date and the 30 trading days immediately preceding the vesting date, respectively. In the event the price of the com-pany\u2019s share has thereby increased by more than 80 percent, 100 percent of the share awards shall vest, and should the share price have increased by 40 percent, 25 percent of the share awards shall vest. In the event of an increase of the share price between 40 and 80 percent, vesting of the share awards will occur linearly. Should the increase of the share price be less than 40 percent, no vesting will occur. The earliest point in time at which vested share awards may be exercised shall be the day falling immediately after the vesting date.The valuation of the share awards is based on a Monte Carlo simulation in accordance with accepted valuation theory. Volatility has been based on the expected volatility of the Vicore share and other listed companies with similar operations. The risk-free interest rate has been derived through an interpolation between a 2-year and 5-year government bond, respectively. The fair value of the share awards at the time of allocation amounts to SEK 10.99 per share award. In order to calculate the value of the share awards in relation to the current performance conditions, a starting value is used that corresponds to the volume-weighted average price paid for the Vicore share over a fixed period, which in this case corresponds to the value of the underlying share at the time of valuation.Co-worker LTIP 2021Co-worker LTIP 2021 is an incentive program intended for members of senior management and key persons in the company. According to the program participants will be granted, free of charge, options subject to three-year vesting that entitle to acquire a maximum of 3,000,000 shares in the company in total.The Board of Directors of the company believes that Co-worker LTIP 2021 will create a strong alignment of the interests of the participants and the interests of the shareholders. Co-worker LTIP 2021 is adapted to the current position and needs of the company. The Board of Directors is of the opinion that Co-worker LTIP 2021 will increase and strengthen the participants\u2019 dedication to the company\u2019s operations, improve company loyalty and that Co-worker LTIP 2021 will be beneficial to both the shareholders and the company. Co-worker LTIP 2021 is a program under which the participants will be granted, free of charge, options. The Board of Directors shall annually resolve upon the allocation of options no later than the day falling three years after the Annual General Meeting 2021 (with each respective date of granting being a \u201cgrant date\u201d). Each Option entitles the holder to acquire one share in the company for a pre-determined exercise price. The exercise price shall correspond to 125 percent of the volume weighted average price of the company\u2019s share on Nasdaq Stockholm for the five trading days preceding the grantdate. The options shall vest over a three-year period with one third each year on the anniversary of the grant day, whereby all options shall vest on the third anni-versary of the grant date, provided that the holder, with some customary exceptions, still is employed by the company. The latest point in time at which vested options may be exercised shall be the fifth anniversary of the grant date.The options are valued according to the so-called Black & Scholes model, which means that the value of the options depends, among other things, on the value of the underlying share, the options\u2019s issue price and life, risk-free interest rate and volatility. The volatility has been based on the expected vola-tility of the Vicore share and other listed companies with similar operations. The risk-free interest rate was equated with the interest rate for Swedish government bonds. The fair value of the options at the time of allocation during 2021 amounts to SEK 8.45 per option. The following inputs have been used in the model:2022 2021Underlying share price 22.00 SEK 20.00 SEKExcercise price 28.75 SEK 26.48 SEKExpected volatility 50.00 % 50.00 %Option life 5 \u00e5r 5 \u00e5rExpected dividends 0 SEK 0 SEKRisk-free interest rate 2.56 % 0.10 %Summary of issued share awards and options2022 2021Average Number Average Number Issued share awards (Board LTIP exercise price of share exercise price of share 2018)per share awardawardsper share awardawardsAt January 1 0 0 0 433,333Forfeited/expired during the year 0 0 0 -433,333At December 31 0 0 0 0A total of 433,333 share awards expired during 2021.2022 2021Average Number Average Number Issued share awards (Board LTIP exercise price of share exercise price of share 2020)per share awardawardsper share awardawardsAt January 1 0 525,000 0 525,000Granted during the year 0 0 0 0Forfeited/expired during the year 0 -291,667 0 0At December 31 0 233,333 0 525,000A total of 291,667 share awards were forfeited during the year.2022 2021Average Number Average Number Issued share awards (Board LTIP exercise price of share exercise price of share 2021)per share awardawardsper share awardawardsAt January 1 0 61,773 0 0Granted during the year 0 0 0 61,773At December 31 0 61,773 0 61,773No share awards have been exercised, forfeited or expired during the year.2022 2021Average Average Issued options (Co-worker LTIP exercise price Number of exercise price Number of 2018)per option optionsper option optionsAt January 1 27.48 1,239,600 27.48 1,239,600Granted during the year 0 0 0 0Forfeited/expired during the year 25.49 -300,000 0 0At December 31 27.99 939,600 27.48 1,239,600A total of 300,000 options were forfeited/expired during the year.2022 2021Average Average Issued options (Co-worker LTIP exercise price Number of exercise price Number of 2021)per option optionsper option optionsAt January 1 26.26 807,600 0 0Granted during the year 28,72 987,850 26.26 807,600Forfeited during the year 27.84 -41,667 0 0At December 31 27.64 1,753,783 26.26 807,600A total of 41,667 options were forfeited during the year.Outstanding share awards and options at year-endDec 31, 2022 Dec 31, 2021Date of Exercise Share awards/Vested Share awards/Vested Program per yearexpirationpriceoptions (%)options (%)Annual Gen-Program share awards eral Meeting 0 233,333 88% 525,000 78%(Board LTIP 2020)2023Annual Gen-Program share awards eral Meeting 0 61,773 75% 61,773 38%(Board LTIP 2021)2024Program 2018 options September 27, 25.26 - - 283,333 100%(Co-worker LTIP 2018)2022Program 2019 options September 27, 26.17 396,267 100% 396,267 92%(Co-worker LTIP 2018)2023Program 2020 options September 24, 29.31 543,333 92% 560,000 68%(Co-worker LTIP 2018)2024Program 2021 options September 16, 26.26 765,933 68% 807,600 15%(Co-worker LTIP 2021)2026Program 2022 options September 27, 28.72 987,850 16% - -(Co-worker LTIP 2021)2027The costs for social security contributions related to share-based incentive programs varies from quarter to quarter due to the change in the underlying share price. Related provisions are reported as non-current liabilities. Total IFRS 2-classified payroll expenses for the incentive programs for the entire duration of the programs amount to 18,967 KSEK. The total costs for the share-based incentive programs for each year is presented below. These costs have had no cash impact. Summary of the total cost of the incentive programs 2022 2021IFRS 2-classified payroll expenses 3,897 3,862Provisions for social security contributions 975 -5,425Total 4,872 -1,563Summary of allotted options and share awards2022 2021Program 2018 Number Number Number Number share awards outstanding outstanding outstanding outstanding (Board LTIP at Jan 1, Granted/at Dec 31, at Jan 1, Granted/at Dec 31, 2018)2022forfeited20222021forfeited2021Former chairman of the Board Leif 0 0 0 83,333 -83,333 0DarnerMember of the 0 0 0 125,000 -125,000 0Board Hans SchikanMember of the Board Maarten 0 0 0 125,000 -125,000 0KraanFormer member of the Board Peter 0 0 0 50,000 -50,000 0Str\u00f6mMember of the 0 0 0 50,000 -50,000 0Board Sara MalcusTotal 0 0 0 433,333 -433,333 02022 2021Program 2020 Number Number Number Number share awards outstanding outstanding outstanding outstanding (Board LTIP at Jan 1, Granted/at Dec 31, at Jan 1, Granted/at Dec 31, 2020)2022forfeited20222021forfeited2021Former chairman of the Board Michael 350,000 -233,333 116,667 350,000 0 350,000Wolff JensenMember of the 175,000 -58,333 116,667 175,000 0 175,000Board Heidi HunterTotal 525,000 -291,667 233,333 525,000 0 525,0002022 2021Program 2021 Number Number Number Number share awards outstanding outstanding outstanding outstanding (Board LTIP at Jan 1, Granted/at Dec 31, at Jan 1, Granted/at Dec 31, 2021)2022forfeited20222021forfeited2021Member of the 20,591 0 20,591 0 20,591 20,591Board Hans SchikanMember of the Board Maarten 20,591 0 20,591 0 20,591 20,591KraanMember of the 20,591 0 20,591 0 20,591 20,591Board Sara MalcusTotal 61,773 0 61,773 0 61,773 61,7732022 2021Program 2018, Number Number Number Number 2019 and 2020 outstanding outstanding outstanding outstanding options (Co-wor-at Jan 1, Granted/at Dec 31, at Jan 1, Granted/at Dec 31, ker LTIP 2018)2022forfeited20222021forfeited2021CEO Carl-Johan 300,000 -100,000 200,000 300,000 0 300,000DalsgaardOther senior 703,750 -150,000 553,750 703,750 0 703,750executivesOther employees 235,850 -50,000 185,850 235,850 0 235,850Total 1,239,600 -300,000 939,600 1,239,600 0 1,239,6002022 2021Number Number Number Number Program 2021 outstanding outstanding outstanding outstanding options (Co-wor-at Jan 1, Granted/at Dec 31, at Jan 1, Granted/at Dec 31, ker LTIP 2021)2022forfeited20222021forfeited2021CEO Carl-Johan 100,000 100,000 200,000 0 100,000 100,000DalsgaardOther senior 436,000 480,000 916,000 0 436,000 436,000executivesOther employees 229,933 407,850 637,783 0 271,600 271,600Total 765,933 987,850 1,753,783 0 807,600 807,600For information about other senior executives, see Note 7 \"Employees and personnel costs\".Note 9 Other operating income2022 2021Exchange rate gains 1,553 1,094Total other operating income 1,553 1,094Note 10 Other operating expenses2022 2021Exchange rate losses 4,784 2,492Total other operating expenses 4,784 2,492Note 11 Financial income2022 2021Financial assets measured at fair value through profit and lossExchange rate gains currency accounts 1,483 0Total 1,483 0Financial assets measured at amortized costInterest income short-term investments 913 646Total interest income calculated using the effective interest method 913 646Total disclosed in net financial income/expenses 2,395 646Note 12 Financial expenses2022 2021Financial assets measured at fair value through profit and lossChange in value for long-term investments -468 -2,121Exchange rate losses currency accounts 0 -431Total -468 -2,552Financial liabilities measured at amortized costInterest expenses other financial liabilities -8 -11Total interest expenses calculated using the effective interest method -8 -11Total disclosed in net financial income/expenses -476 -2,563Not 13 Tax2022 2021Current tax 0 0Change in deferred tax regarding temporary differences 384 254Recognized tax 384 254Reconciliation of effective tax rates 2022 2021Loss before tax -288,806 -296,735Tax according to applicable tax rate 20.6% (20.6%) 59,494 61,127Non-deductable expenses -682 -95Tax effect non-taxable income 0 1,118Tax effect unrecognized tax assets -58,428 -61,896Change in deferred tax 384 254Recognized tax 384 254Effective tax rate 0% 0%The group has no tax items that are recognized in other comprehensive income, but there are issue costs booked directly against shareholder\u2019s equity.Information about deferred tax liabilitiesIn the table below, the tax effect of the temporary differences is specified: 2022 2021 Deferred tax liabilityDec 31 Dec 31Intangible assets 641 1,026Tax provision for pension premium 264 184Carrying amount 905 1,210Tax loss carryforwardsTax loss carryforwards for which deferred tax assets have not been recognized in the balance sheet amounted to 1,023,731 KSEK (727,791 KSEK). These carryforwards have no time limit. Deferred tax assets have not been recognized for these items, as it is unlikely that the group in a foreseeable future will utilize them to offset future taxable profits. For further information about tax loss carryforwards, see Note 2 \"Judgements and accounting estimates\".Note 14 Earnings per shareEarnings per share before and after dilution 2022 2021Profit for the year attributable to shareholders of the parent company -288,423,230 -296,480,577Average number of ordinary shares 72,214,440 69,678,461Earnings per share before and after dilution -3.99 -4.25The average number of outstanding shares has been adjusted for bonus shares in new stock issued targeted towards existing shareholders. Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding for the dilution effect from all potential ordinary shares. These potential ordinary shares are attributable to the options and share awards allocated to senior execu-tives, other employees and certain board members during the years 2018-2022. For further information, see Note 8 \"Share-based payments\". If there is a loss for the year, the options are not treated as dilutive. Neither are the options considered dilutive if the exercise rate, including the addition of the value of remaining future services to be recognized during the vesting period, exceeds the average trading price for the period. There is no dilution effect for potential ordinary shares as there was a loss for the year, as demonstrated above.For more information about the changes of the number of outstanding shares, see Note 24 \"Sharehold-ers\u2019 equity\".Note 15 Patents, licenses and similar rights2022 2021 Dec 31Dec 31Opening cost 75,192 75,192Additions for the year 6,000 0Disposals -2,000 0Closing accumulated cost 79,192 75,192Opening amortizations -7,765 -4,437Amortizations for the year -3,327 -3,328Closing accumulated amortizations -11,092 -7,765Closing carrying amount 68,100 67,427Amortizations Amortization refers to previously acquired intangible assets. This consists of a patent portfolio related to C21, whose main patent expires in the United States in September 2024. Amortization began in Septem-ber 2019 and is amortized over its estimated useful life, which is the remaining patent period. Amortization has not yet begun for the group's other intangible assets.Impairment testingTo test the value of acquired intangible assets, Vicore uses a probability-adjusted discounted cash flow model based on fair value. The value in use for C21, IMiD and C106 is determined by calculating the present value of the estimated future cash flows and adjusting these in order to take the development risk into account. The valuation considers the cash flows over the projects\u2019 estimated remaining useful life, but does not involve calculation of any residual value thereafter. The methodology used is an accepted one for impairment testing within the biopharmaceutical industry. The measurement is attributed to Level 3 in the fair value hierarchy and comprises the material assumptions specified below: \u2022 Revenue- and cost forecasts for C21 stretches over 7 years for the US and 10 years for the EU and Japan, that is, during the period in which the company has orphan drug protection in each market. Revenue- and cost forecasts for IMiD and C106 stretches over 20 years. \u2022 Revenue is calculated using estimations based on available data of different types considered indica-tors, e.g. forecasts of total market size, growth, anticipated market share of the product, competition from rival products and assessed price level. Market, growth, anticipated market share of the product and assessed price level is derived from secondary sources, accepted industry assumptions and assumptions made by Vicore.\u2022 Costs comprise development expenditures as well as direct and indirect project costs based on Vicore\u2019s business plan. Operating margins are derived from secondary sources, accepted industry assumptions and assumptions made by Vicore.\u2022 The present value of the cash flows is calculated and adjusted to reflect the probability of success for the project. This probability is based on accepted assumptions regarding the possibility for a corre-sponding product to go to market from the current development stage. The probability of success for C21 is estimated at 25.6%, IMiD at 7.2%, and C106 at 15.3%.\u2022 The weighted average pre-tax cost of capital has been estimated at 14% (14%). The most critical assumptions mainly consist of assumptions made about market size, market share and price level. As with many pharmaceutical development projects, the results of the development work may be binary in the sense that the project can either be developed according to plan or must be cancelled altogether. Where appropriate, the valuation has been calibrated against completed share issues with external investors.The impairment assessment for December 31, 2022, has not demonstrated a need for any impairments. No reasonable changes in the assumptions and estimates made would lead to an impairment.Note 16 Equipment 2022 2021 Dec 31Dec 31Opening cost 147 147Closing accumulated cost 147 147Opening depreciations -63 -34Depreciations for the year -30 -29Closing accumulated depreciations -93 -63Closing carrying amount 54 84Note 17 Long-term investments2022 2021 Dec 31Dec 31Opening carrying amount 5,409 7,530Change in value in profit/loss -469 -2,121Reclassification to short-term investments -4,940 0Closing carrying amount 0 5,409Vicore holds as of December 31, 2022, a total of 91,829 shares in I-Tech AB (publ). The holdings were reclas-sified in December, 2022, to short-term investments. The holdings were divested on January 4, 2023. Note 18 Financial assets and liabilitiesFinancial assets and liabilities at December 31, 2022Financial assets/ liabilities Financial assets/ Total measured at fair value liabilities measured carrying through profit and lossat amortized costamountFinancial assetsOther current receivables 0 338 338Short-term investments 4,940 0 4,940Cash and cash equivalents 0 256,803 256,803Total 4,940 257,141 262,081Financial liablilitiesContract liability 0 64 64Trade payables 0 23,495 23,495Other liabilities 0 70 70Accrued expenses 0 14,381 14,381Total 0 38,010 38,010The maximum credit risk of the financial assets consists of the net amounts of the reported values in the table above The group has not received any pledged assets for the financial net assets.Financial assets and liabilities at December 31, 2021Financial assets/ liabilities Financial assets/ Total measured at fair value liabilities measured at carrying through profit and lossamortized costamountFinancial assetsLong-term investments 5,409 0 5,409Other current receivables 0 60 60Accrued income 0 281 281Short-term investments 0 77,000 77,000Cash and cash equivalents 0 294,199 294,199Total 5,409 371,540 376,949Financial liablilitiesContract liability 0 320 320Trade payables 0 23,984 23,984Accrued expenses 0 35,311 35,311Total 0 59,615 59,615The maximum credit risk of the financial assets consists of the net amounts of the reported values in the table above The group has not received any pledged assets for the financial net assets.Fair value measurementIFRS 13, Fair Value Measurement contains a valuation hierarchy regarding inputs to the measurements. This measurement hierarchy is divided into three levels, which comprise:Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilitiesLevel 2 - Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as price quotations) or indirectly (that is, derived from price quotations)Level 3 - Inputs for the asset or liability that are not based on observable market data (that is, non-observ-able inputs)Long-term investmentsInvestments in financial fixed assets are measured at fair value with changes in value in profit and loss. Investments in listed shares are measured at fair value according to Level 1 in the valuation hierarchy. Listed investments are measured on the basis of their share price on the closing day.Other financial assets and liabilitiesFor other current receivables and liabilities, short-term investments, cash and cash equivalents, trade payables, and accrued income and expenses with a short maturity, the carrying amount is considered a reasonable estimate of the fair value.Note 19 Financial risksThrough its operations, Vicore is exposed to various types of financial risk; credit risks, market risks (foreign exchange risk, interest rate risk and other price risks) and liquidity risks (including refinancing risk). The group\u2019s overall risk management objective focuses on the unpredictability of financial markets and strives to minimize potentially unfavorable consequences for the group\u2019s financial position and performance.The Board of Directors has overall responsibility for managing financial risks and internal controls related to financial transactions. Financial risks and transactions are managed centrally by the parent company through the group\u2019s CFO and CEO. The overall objective in terms of financial risks is: to provide cost-effec-tive financing and cash management, to ensure that all payment commitments are processed at the right time, to ensure that all financial transactions are organized in a way that supports the group in achieving the financial key ratios and ensure that risk exposures relating to credit risk, market risks and liquidity risk are reduced to an acceptable level.The Board of Directors establishes written principles both for the overall risk management and for spe-cific areas such as credit risks, foreign exchange risks, interest rate risks, refinancing risks, liquidity risks and the use of derivative instruments and the handling of excess liquidity. The group does not currently use derivatives, but allows hedging of currency in certain situations.Credit risk Credit risk is the risk that the group\u2019s counterparty of a financial instrument cannot fulfill its obligation and thereby causes a financial loss for the group. Given the nature of the group\u2019s business, with no foreseen revenues, credit risk is not a material issue at this stage of the company\u2019s development. However, some credit risk exists in the group\u2019s cash management, which is managed through Vicore\u2019s treasury policy.Financial credit risk The financial assets that are covered by provisions for expected credit losses according to the general method consist of cash and cash equivalents. Vicore applies a rating-based method in combination with other known information and forward-looking factors for assessing expected credit losses. The group has defined default as when payment of the claim is 90 days overdue or more, or if other factors indicate a suspension of payments. Significant increase in credit risk has not been considered to exist for any receiv-able or asset on the reporting date. Such assessment is based on whether payment is 30 days overdue or more, or if significant deterioration of the rating occurs, entailing a rating below investment grade. In cases where the amounts are not deemed to be insignificant, a provision for expected credit losses is also recognized for these financial instruments.The assessment has been made that there has been no significant increase in credit risk for any of the group\u2019s financial assets. There counterparties do not have credit ratings, except for cash and cash equivalents where the counterparties have credit risk ratings of AA-, A+ and A.Market risksMarket risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risks are according to IFRS divided into three types: foreign exchange risk, interest rate risk and other price risks. Foreign exchange risk is the market risk with the greatest impact on the group as the financing received shall cover for research and development costs mainly in foreign currencies.The group does not currently have any loans that expose it to interest rate risks. Interest risk may occur in short term cash management, and is regulated by maximum maturities.The group is partly exposed to other price risks from investments in listed shares. However, the risks associated with the investments have not been considered to be significant.Foreign exchange risk Foreign exchange risk is the risk that the fair value of or future cash flow from a financial instrument may vary due to changes in foreign exchange rates. Foreign exchange risk relates to the risk that fluctu-ations in exchange rates will have a negative impact on the group\u2019s P&L, balance sheet or cash flow.Transaction currency riskThe main exposure derives from the group\u2019s expenses in foreign currencies. This exposure is referred to as transaction exposure. The company'sdevelopment costs for C21 are mainly paid in EUR. As a result, the company is subject to exchange rate risks in relation to payment flows within Sweden and the eurozone, such as fluctuations where the exchange rate changes from the time an agreement is entered into until its payment is to be made in accordance with the agreement. Foreign exchange hedging is decided by the Board of Directors based on cash flow forecasts. In accordance with the company's policy for financial risk, the company exchanges EUR at a level of 60-100% of expected flows. See the table below for the level of exposure in each currency.Operating Operating incomeexpensesForeign exchange exposure 2022 (%)GBP - 8%EUR - 53%DKK - 3%USD - 5%SEK - 31%Foreign exchange exposure 2021 (%)GBP 100% 7%EUR - 52%DKK - 2%USD - 2%SEK - 37%Operating expenses in the table above are excluded from payroll expenses.As indicated in the table above, the group\u2019s main transaction exposure consists of EUR (EUR in 2020). A 10% stronger EUR against SEK would have a negative impact on the profit after tax and shareholders\u2019 equity by approximately 13,914 KSEK (14,191 KSEK).Refinancing riskRefinancing risk refers to the risk that cash and cash equivalents are unavailable and that financing can only be obtained partially, not at all or at an elevated cost. If the company's development projects fail or are delayed, it may negatively affect the company's ability to raise external capital. In addition, market conditions, the general availability of capital as well as uncertainty and/or disturban-ces in the capital markets can affect the company's ability to raise, and the availability of, such financing. There is a risk that new capital cannot be raised when needed, that new capital can only be raised at terms and conditions unsatisfactory for the company, or that available capital is not sufficient for the company's development plans and objectives. In the event of one or more risks occurring, it may have significant negative effects on the Company\u2019s financial position in the form of, for example, a significantly increased debt/equity ratio, increased expenses for loans and other financing.Liquidity risk Liquidity risk is the risk that the group will encoun-ter difficulties in fulfilling its obligations related to financial liabilities. The Board of Directors manage liquidity risk by continuously following up the cash flow to reduce liquidity risk and ensure the solvency of the group.Vicore uses rolling forecasts to ensure that the company has sufficient cash assets to meet its operational requirements. This monitoring takes the form of reporting to the Board, whereby outcomes and forecasts are compared with the budget that is produced and approved by the Board each year.Surplus liquidity in Vicore, in excess of what is required to manage working capital requirements, is from time to time invested in interest-bearing current accounts. At the balance sheet date, Vicore had short-term investments in fixed-rate accounts of 0 KSEK (77,000 KSEK). In addition to this, Vicore had bank deposits of 256,803 KSEK (294,199 KSEK) at the balance sheet date.The group\u2019s contractual and undiscounted interest payments and financial liability repayments are shown in the table below. Amounts in foreign currencies have been translated into SEK at the closing rate on the reporting date. Financial instruments with a variable interest rate have been calculated using the interest rate at the reporting date. Liabilities have been included in the earliest period during which repayment may be required. Dec 31, 2022<1 month 1-3 months >3 monthsMaturity analysisContract liability 21 43 0Trade payables 23,446 49 0Other short-term liabilities 70 0 0Accrued expenses 4,856 5,194 4,331Total 28,393 5,286 4,331Dec 31, 2021<1 month 1-3 months >3 monthsMaturity analysisContract liability 21 42 257Trade payables 23,785 198 0Accrued expenses 0 13,934 21,377Total 23,806 14,174 21,634Capital managementThe group\u2019s goals regarding the capital structure are to ensure financing of the company\u2019s development and business plan. Equity or financing related to equity is expected to be the most realistic and possible alternative in the near future.No change occurred in the group\u2019s capital management during the year. None of the group companies are subject to external capital requirements.Note 20 Prepaid expenses and accrued income2022 2021 Dec 31Dec 31Prepaid rental charges 109 214Prepaid insurances 626 591Prepaid research and development expenses 4,538 3,123Other prepaid expenses 594 1,106Total 5,867 5,034Note 21 Short-term investments2022 2021 Dec 31Dec 31Fixed-rate account, SBAB 0 77,000Accrued interest income 0 281Reclassification from long-term investments (I-Tech AB) 4,940 0Total 4,940 77,281Note 22 Cash and cash equivalents 2022 2021 Available balancesDec 31Dec 31SEK 256,799 232,568EUR 4 61,631Total 256,803 294,199Note 23 Group companiesShare of equity and voting rights2022 2021 Company Principal activityDec 31Dec 31Vicore Pharma Holding AB Own and manage shares in subsidiaries Parent companyResearch and development of Vicore Pharma AB100% 100%pharmaceutical productsResearch and development of INIM Pharma AB100% 100%pharmaceutical productsNote 24 Shareholders\u2019 equityShare capital and other contributed capitalNumber of Other contributed SEKordinary shares Share capitalcapitalAt January 1, 2021 60,418,239 30,209,119 702,052,950Issue in kind, November 2, 2020, registered February 142,054 71,027 2,928,97322, 2021New share issue, February 22, 2021, registered March 11,200,000 5,600,000 312,821,8959, 2021Share-based payments 0 0 3,861,698At December 31, 2021 71,760,293 35,880,146 1,021,665,516At January 1, 2022 71,760,293 35,880,146 1,021,665,516New share issue, June 17, 2022, registered June 28, 87,686 43,843 2,956,1572022New share issue, December 8, 2022, registered Decem-10,000,000 5,000,000 182,292,382ber 28, 2022Share-based payments 0 0 3,897,141At December 31, 2022 81,847,979 40,923,989 1,210,811,196Note 25 Other provisions2022 2021 Social security contributions related to share-based incentive programsDec 31Dec 31Opening amount 752 6,177Provisions for the year 975 -5,425Total 1,727 752For more information about incentive programs, see Note 8 \"Share-based payments\".Note 26 Accrued expenses and deferred income2022 2021 Dec 31Dec 31Accrued personnel-related expenses 3,582 4,644Accrued expenses, research and development 13,166 35,036Accrued expenses, other 1,473 459Total 18,221 40,139Note 27 Supplementary information to the cash flow statement2022 2021 Adjustment for items not included in the cash flowDec 31 Dec 31Depreciations 3,612 3,598Loss on disposal of intangible asset 2,000 0Incentive programs, payroll expenses 3,897 3,862Incentive programs, social security contributions 975 -5,425Provision for payroll tax, pension premium 76 64Total 10,560 2,099Note 28 Related-party transactionsRelated parties are defined as individuals with holdings of more than ten percent, members of the group\u2019s senior management, meaning the Board of Directors and senior executives, as well as their immediate family members. For information about remuneration to senior executives and the Board of Directors, see Note 7 \"Employees and personnel costs\".Note 29 Contingent liabilitiesBelow a summary of material agreements which the company has entered into during the most recent years:Agreement with Emeriti Bio ABVicore Pharma AB (\"Vicore Pharma\") entered into a collaboration and development agreement with Emeriti Bio AB on August 24, 2016, which was expanded on November 1, 2017. The main purpose of the agreement is to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor (AT2R). On November 2, 2020, the parties expanded their collaboration and development agreement in connection with the acquisition of a number of new intellectual proporty rights as part of the development of new AT2R agonists from HaLaCore Pharma AB, where HaLaCore Pharma AB became a new party to the agreement. The agreement is valid until there is no longer any obligation to pay Emeriti Bio AB and HaLaCore Pharma AB. For Emeriti Bio AB\u2019s and HaLaCore Pharma AB's development work, Vicore Pharma pays con-sultancy fees, possible milestone compensation subject to achievement of predefined development goals. Vicore Pharma owns all results. The total maximum payments in the form of milestone compensation under the agreement is limited to 49.5 MSEK. In 2020, a milestone payment of 1,000 KSEK (250 KSEK) was paid to Emeriti Bio AB in connection with the filing of a patent application by Vicore Pharma. As compensation for the acquisition of intellectual property rights, HaLaCore received a one-time payment of 6 MSEK in 2020, divided between 3 MSEK in cash and 142,054 newly issued shares in Vicore, corresponding to approximately 3 MSEK. In June 2022, a milestone payment of approximately 6 MSEK was paid to Emeriti Bio AB and HaLaCore Pharma AB in connection with the first subject being dosed in the phase 1 study with C106. This is reported in Note 15 \"Patents, licenses and similar rights\".Agreement with Alex Therapeutics ABVicore Pharma AB (\"Vicore Pharma\") entered into a collaboration and development agreement with Alex Therapeutics on April 23, 2021. The main purpose of the agreement is to develop a digital app in interstitial lung diseases, such as IPF. Within the scope of the collaboration and development agreement, Vicore Pharma pays certain milestone payments if the collaboration leads to predetermined development goals as well as royalties on sales. At the entering of the agreement, Vicore paid a one-time payment amounting to 0.8 MEUR.Note 30 Events after the balance sheet date\u2022 In January, Vicore divested its entire holding of 91,829 shares in I-Tech AB (publ). As of December 31, 2022, the value of the financial asset was approximately 4.9 MSEK. \u2022 In March, Vicore was awarded Innovation Passport designation by the UK regulatory agency MHRA (Medicines and Healthcare products Regulatory Agency) for C21 in IPF. ", "dimensions": { "concept": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-31-2": { "value": "Note 1 Accounting principlesCurrencyFunctional currency and reporting currencyFunctional currency is the currency in the primary economic environments in which the companies operate. The parent company\u2019s functional currency is the Swedish kronor, which is also the reporting currency for the parent company and the group. Unless otherwise stated, all amounts are rounded to the nearest thousand (KSEK).Foreign currency transactionsTransactions in foreign currency are translated to the functional currency at the exchange rate as on the transaction date. Monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rate on the balance sheet date. Exchangerate differences that arise are recognized in the profit/loss for the year. Exchange gains and exchange losses on operating receivables and operating liabilities are reported in operating results, while exchange gains and exchange losses on financial receivables and liabilities are reported as financial items.perating segmentsOperating segments are reported in a way that corresponds with internal reporting structures. The profit/loss generated by a business segment is then followed up by the company\u2019s chief operating decision maker, who is responsible for assessing the profit/loss figures and allocating resources to the business segment. In the group, this function is identified as the company\u2019s CEO.An operating segment is a component of the group that engages in business activities from which it may earn revenues and incur expenses, and for which discrete financial information is available. Vicore does not divide its business into different segments, instead it sees the entire business of the group as one segment. This followsthe company\u2019s internal organization and reporting structures.Government grantsGovernment grants are reported in the statement of financial position and the statement of comprehensive income when there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received. The grant is recognised as incomeover the period necessary to match them with Pension obligationsThe group only has defined contribution pension plans. In defined contribution plans, the group pays fixed contributions to a separate entity and has no legal or constructive obligation to pay further contributions if this entity does not have sufficient assets to pay all the remuneration to employees connected with the employees\u2019 service during the current or prior periods. Therefore, the group has no additional risk. For the group\u2019s obligations regarding contributions for defined contribution plans, these are reported as an expense in the consolidated profit/loss as the benefits are earned.Incentive programsThere are four types of share-based incentive programs in the group: two option programs for employees, and two share awards programs for certain board members. The option and share awards have been granted free of charge and are settled with equity instruments.The fair value of share-based payments is accounted for as personnel costs. The fair value of the employee stock options is determined at grant date with the Black-Scholes model for pricing of options. For the share awards, the fair value is determined at the time of allocation using a Monte Carlo simulation of future stock price development.The cost is reported, along with a corresponding increase in equity, during the period in which the vesting conditions are fulfilled, up to and including the date when the persons concerned are fully entitled to the compensation.The accumulated cost included in each reporting period shows to what extent the vesting period has been recognised with an estimate of the number of share-related instruments that eventually will be vested.Social security contributions attributable to share-related instruments to employees as compensation for purchased services must be expensed over the periods during which the services are performed. This cost must then be calculated using the same valuation model that was used whenthe related costs, for which they are intended tocompensate, on a systematic basis.Leasing agreementThe group\u2019s leasing portfolio consists of a fewoperating leases for premises, which are the two classes of leased assets presented by the group.The leasing agreements are reported as contract assets with a corresponding lease liability on the daythat the leased asset is available for use by the group.Short-term leases and low value leases are excluded.Each leasing payment is divided between amortiza-tion of the lease debt and financial cost. The financialcost shall be distributed over the lease period so thateach accounting period is charged with an amount corresponding to a fixed interest rate for the liabilityreported during each period.The leasing period is determined as the non-cancel-lable period together with both periods covered by an option to extend the lease if the lessee is reasonablysure to take advantage of that option, and periods covered by an opportunity to terminate the lease if thelessee is reasonably sure not to exercise that option.The group's leasing liabilities are recognized at the present value of the group's future leasing fees. Leasing payments have been discounted with thegroup's marginal loan interest rate.The group's contract assets are recognized at cost and initially include the present value of theleasing liabilities, adjusted for leasing fees paid onor before the commencement date and initial directexpenses. Recovery costs are included in the asset ifa corresponding provision regarding recovery costs has been identified. The contract asset is amortizedon a straight-line basis over the shorter of the asset'suseful life and the duration of the lease.Employee benefitsShort-term remunerationShort-term remuneration to employees, such as salary, social security contributions, holiday pay and bonus, is expensed when the employees perform the services.the options were issued. The provision made shall be reassessed at each reporting date based on a calculation of the amount social charges that may be payable when the instruments are settled.Financial incomeFinancial income consists of capital gains on and dividend incomes from financial fixed assets. Dividend income is recognized when the right to receive a dividend has been established.Exchange rate gains and losses are reported net.Financial costsFinancial costs consist mainly of interest expenseson loans. Exchange rate gains and losses are reported net.Income taxesIncome taxes consist of current tax and deferred tax. Income taxes are recognized in profit or loss for the year, except when the underlying transac-tion is recognized in other comprehensive incomeor equity, in which case the tax effect is recognized in other comprehensive income or equity.Current taxCurrent tax is the tax that must be paid or received for the current year, with the application of the tax rates that have been decided, or in practice decided, on the balance sheet date. Current tax also includes adjustments to the current tax attributable to previous periods.Earnings per shareEarnings per share before dilution are calculated as profit or loss attributable to the parent company shareholders divided by the weighted average number of ordinary shares outstanding during the period.Earnings per share after dilution are calculated as profit or loss attributable to the parent company shareholders divided, in some cases adjusted, by the sum of the weighted average number of ordinary shares and potential ordinary shares that may give rise to dilution effects. A dilution effect of potential ordinary shares is recognized only if a translation into ordinary shares would lead to a reduction of earnings per share after dilution.Acquired intangible assetsIntangible assets in the group consist of patents, licenses and similar rights. They are valued at cost that is decreased by accumulated depreciation andany accumulated impairment losses.An intangible asset is recognized if it is probable that the asset will generate future economic benefits for the group, the criteria for capitalization are met and the costs can be measured reliably. An intangible asset is valued at cost when it is includedfor the first time in the financial report. Intangible assets with finite useful lives are reported at cost less depreciation and any impairment losses. Intangible fixed assets with finite useful lives are depreciated linearly over the asset\u2019s estimated useful life. Intangible assets with indefinite useful lives are instead tested annually for impairment.Intangible assets with finite and indefinite useful lives are reviewed for impairment requirements in cases where there are indications that a write-down may be needed. The useful life of intangible assets is reviewed at each balance sheet date and adjusted if necessary.Capitalization of development expenditureThe expenses that arise during the development phase are capitalized as intangible assets when, according to management\u2019s assessment, they are likely to result in future economic benefits for the group, the criteria for capitalization are met and the costs can be measured in a reliable way. Otherwise,development expenses are expensed as normal operating expenses.The group only has acquired intangible assets.Depreciation principlesDepreciation begins when the asset can be used, i.e. when it is in the place and in the condition required to be able to use it in the way managementintends. The estimated useful life for intangible fixed assets with a finite useful life is 5 years. Depre-ciation is made on a straight-line basis over theestimated useful life of the asset, which coincides with the remaining patent period for the product. Tangible fixed assetsTangible fixed assets are reported in the group at cost after deductions for accumulated deprecia-tion and any accumulated impairment losses. The cost includes the purchase price and any costs directly attributable to the asset to bring it in place and in condition to be utilized in accordance with the purpose of the acquisition.The carrying amount of an asset is derecognized from the balance sheet when disposing or divesting, or when no future economic benefits are expected from use or disposing/divesting of the asset. Gains or losses arising from the sale or disposal of an asset consist of the difference between the selling price and the asset\u2019s carrying amount with the deduction of direct sales costs. Gains and losses are reported as other operating income/expenses.Additional expensesAdditional expenses are added to the asset\u2019s carrying amount only if it is probable that the future economic benefits associated with the asset will be leveraged by the group and that the cost of the asset can be measured reliably. All other additional expenses are reported as an expense during the period they arise. Repairs are expensed on an ongoing basis.Depreciation principlesThe depreciable amount shall be allocated on a systematic basis over the asset\u2019s estimated useful life. Used depreciation methods, residual values and useful lives are reviewed at the end of each year.The estimated useful lives are:Equipment ...............................5 yearsImpairment of non-financial assetsThe group\u2019s reported assets are assessed in cases where there are indications of a decline in value of tangible or intangible assets, i.e. whenever events or changes in circumstances indicate that the fair value is not recoverable. Furthermore, the group\u2019s development projects are reviewed annually for impairment requirements until they are available for use. This is done regardless of whether there are indications of a decline in value or not.An impairment is recognized when an asset\u2019s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of the asset\u2019s fair value less the cost of sale on the one hand and the value in use on the other. When assessing impairment, assets are grouped at the lowest level where there are separate identifiable cashflows (cash-generating units). When the need for impairment has been identified for a cash-gener-ating unit (group of units), the impairment amount is distributed proportionally among the assets included in the cash-generating unit (group of units).A previously recognized impairment is reversed if the recovery amount is deemed to exceed thefair value. Reversal does not occur with an amount that is greater than what the fair value would have been recorded to if the impairment had not been recognized in previous periods. Any reversals arereported in the income statement.Financial assets and liabilitiesA financial asset or financial liability is recognized in the balance sheet when the group becomes a party according to the instrument\u2019s contractualterms. A financial asset is removed from thebalance sheet when the rights in the agreement are realized, expire or when the group loses control over them. The same applies to a part of a financial asset. A financial liability is removed from the balance sheet when the obligation in the agreement is fulfilled or otherwise extinguished. The same applies to a part of a financial debt.Acquisitions and divestments of financial assets are reported on the trade date. The trade date constitutes the day when the company undertakes to acquire or divest the asset.Financial instruments are classified on initial recognition, including on the basis of what purpose the instrument was acquired and man-aged. This classification determines the valuation Classification and valuation of financial assetsThe classification of financial assets that are debt instruments, is based on the group\u2019s business model for managing the asset and the nature of theasset\u2019s contractual cash flows.Assets are classified according to:Amortized costFair value through profit or loss, orFair value through other comprehensive incomeThe group\u2019s financial assets that are classified at amortized cost include accounts receivable, certain other receivables, short-term investments, and cash and cash equivalents. Financial assets classified at amortised cost are initially measured at fair value with the addition of transaction costs. After initial recognition, the assets are valued at amortized cost after a deduction of a loss reserve for expected credit losses. Assets classified at amortized cost are held according to the business model to collect contractual cash flows, which are solely payments of principal and interest on the outstanding principal amount.The group\u2019s financial assets that are classified at fair value through profit or loss relate to holdings in listed and non-listed shares.Impairment of financial assetsThe group\u2019s impairment model is based on expected credit losses, and takes into account prospective information. A loss reserve is made when there is an exposure to credit risk, usually at initial recognition for an asset or receivable. Classification and valuation of financial liabilitiesThe group\u2019s financial liabilities consist of accounts payable and other current liabilities, which are allclassified at amortized cost. Financial liabilities recognized at amortized cost are initially measuredat fair value including transaction costs. After the initial recognition, they are valued according to the effective interest method.Cash and cash equivalentsCash and cash equivalents consist of cash and balances as well as immediately available credit balances with banks and corresponding financial institutions.Contingent liabilitiesA contingent liability is recognised when there is a possible commitment that arises from past events and whose existence is confirmed only by one or more uncertain future events, or when there is a commitment that is not reported as a liability or provision due to it being unlikely that an outflow of resources will be required.Cash flowCash and cash equivalents consist of available cash, bank credit balances and other liquid investments with an original maturity of less than three months, which are exposed to insignificant value fluctuation. Incoming and outgoing payments are reported in the cash flow statement. The cash flow statement has been prepared in accordance with the indirect method.Foreign exchange risk Foreign exchange risk is the risk that the fair value of or future cash flow from a financial instrument may vary due to changes in foreign exchange rates. Foreign exchange risk relates to the risk that fluctu-ations in exchange rates will have a negative impact on the group\u2019s P&L, balance sheet or cash flow.Transaction currency riskThe main exposure derives from the group\u2019s expenses in foreign currencies. This exposure is referred to as transaction exposure. The company'sdevelopment costs for C21 are mainly paid in EUR. As a result, the company is subject to exchange rate risks in relation to payment flows within Sweden and the eurozone, such as fluctuations where the exchange rate changes from the time an agreement is entered into until its payment is to be made in accordance with the agreement. Foreign exchange hedging is decided by the Board of Directors based on cash flow forecasts. In accordance with the company's policy for financial risk, the company exchanges EUR at a level of 60-100% of expected flows. See the table below for the level of exposure in each currency.Operating Operating incomeexpensesForeign exchange exposure 2022 (%)GBP - 8%EUR - 53%DKK - 3%USD - 5%SEK - 31%Foreign exchange exposure 2021 (%)GBP 100% 7%EUR - 52%DKK - 2%USD - 2%SEK - 37%Operating expenses in the table above are excluded from payroll expenses.As indicated in the table above, the group\u2019s main transaction exposure consists of EUR (EUR in 2020). A 10% stronger EUR against SEK would have a negative impact on the profit after tax and shareholders\u2019 equity by approximately 13,914 KSEK (14,191 KSEK).Note 28 Related-party transactionsRelated parties are defined as individuals with holdings of more than ten percent, members of the group\u2019s senior management, meaning the Board of Directors and senior executives, as well as their immediate family members. For information about remuneration to senior executives and the Board of Directors, see Note 7 \"Employees and personnel costs\".", "dimensions": { "concept": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f7117": { "value": "Vicore Pharma Holding AB", "dimensions": { "concept": "ifrs-full:NameOfParentEntity", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f7118": { "value": "Vicore Pharma Holding AB", "dimensions": { "concept": "ifrs-full:NameOfUltimateParentOfGroup", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f7123": { "value": "limited liability company", "dimensions": { "concept": "ifrs-full:LegalFormOfEntity", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f7125": { "value": "Gothenburg,", "dimensions": { "concept": "ifrs-full:DomicileOfEntity", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f7126": { "value": "Sweden", "dimensions": { "concept": "ifrs-full:CountryOfIncorporation", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f7130": { "value": "Stockholm", "dimensions": { "concept": "ifrs-full:AddressOfRegisteredOfficeOfEntity", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f7131": { "value": "Stockholm", "dimensions": { "concept": "ifrs-full:PrincipalPlaceOfBusiness", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-37-2": { "value": "Vicore\u2019s consolidated accounts have been preparedin accordance with the International Financial Reporting Standards (IFRS) issued by the Interna-tional Accounting Standards Board (IASB) as well as the interpretations from the IFRS Interpretation Committee (IFRS IC) as adopted by the European Union (EU). Furthermore, the group also applies theAnnual Accounts Act (1995: 1554) and the SwedishFinancial Reporting Board\u2019s recommendation RFR 1 \u201dSupplementary Accounting Rules for Groups\u201d. ", "dimensions": { "concept": "ifrs-full:StatementOfIFRSCompliance", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-37-3": { "value": "Vicore\u2019s consolidated accounts have been preparedin accordance with the International Financial Reporting Standards (IFRS) issued by the Interna-tional Accounting Standards Board (IASB) as well as the interpretations from the IFRS Interpretation Committee (IFRS IC) as adopted by the European Union (EU). Furthermore, the group also applies theAnnual Accounts Act (1995: 1554) and the SwedishFinancial Reporting Board\u2019s recommendation RFR 1 \u201dSupplementary Accounting Rules for Groups\u201d. ", "dimensions": { "concept": "ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-37-4": { "value": "Vicore\u2019s consolidated accounts have been preparedin accordance with the International Financial Reporting Standards (IFRS) issued by the Interna-tional Accounting Standards Board (IASB) as well as the interpretations from the IFRS Interpretation Committee (IFRS IC) as adopted by the European Union (EU). Furthermore, the group also applies theAnnual Accounts Act (1995: 1554) and the SwedishFinancial Reporting Board\u2019s recommendation RFR 1 \u201dSupplementary Accounting Rules for Groups\u201d. ", "dimensions": { "concept": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-47-2": { "value": "Preparing financial statements in accordance with IFRS requires the company management to make estimates for accounting purposes. These assessments and estimates are based on historical experiences, as well as other factors that are considered to be reasonable during the current circumstances. The actual result can deviate from these estimates and assessments.", "dimensions": { "concept": "ifrs-full:DisclosureOfGoingConcernExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-55-2": { "value": "instruments or debt instruments, which arise are reported directly in the profit/loss for the year. For business combinations where the transferred remuneration exceeds the fair value of acquired assets and assumed liabilities that are reported separately, the difference is reported as goodwill. When the difference is negative, a so-called bargainpurchase, this is reported directly in the profit/loss for the year.When acquiring an asset, the acquisition value is allocated to the individual identifiable assets and the debts, based on their relative fair values. Such a transaction does not give rise to goodwill.Eliminated transactions during consolidationIntra-group receivables and liabilities, income or expenses and unrealised gains or losses which arise from intra-group transactions between group companies are eliminated in the preparation of the consolidated accounts. Unrealised gains arising from transactions with associated companies are eliminated to the extent which corresponds to the group\u2019s ownership in the company. Unrealised losses are eliminated in the same way, but only to the extent that there is no impairment of the asset.Subsidiaries are all the companies over which Vicorehas a controlling influence. The group controls acompany when it is exposed to, or has rights to, var-iable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Subsidiaries are included inthe consolidated accounts as of the date on which the controlling influence is transferred to the group. They are excluded from the consolidated accounts asof the date on which the controlling influence ceases.Subsidiaries are reported according to the acqui-sition method. The method implies that acquiring a subsidiary is considered a transaction, wherebythe group indirectly acquires the subsidiary\u2019s assets and liabilities. In the acquisition analysis, the fair value of acquired identifiable assets and assumed liabilities, as well as any holdings without controlling influence, is determined on the acquisition date. Transaction costs, excluding transaction costs attributable to the issue of equity ", "dimensions": { "concept": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-79-2": { "value": "CurrencyFunctional currency and reporting currencyFunctional currency is the currency in the primary economic environments in which the companies operate. The parent company\u2019s functional currency is the Swedish kronor, which is also the reporting currency for the parent company and the group. Unless otherwise stated, all amounts are rounded to the nearest thousand (KSEK).Foreign currency transactionsTransactions in foreign currency are translated to the functional currency at the exchange rate as on the transaction date. Monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rate on the balance sheet date. Exchangerate differences that arise are recognized in the profit/loss for the year. Exchange gains and exchange losses on operating receivables and operating liabilities are reported in operating results, while exchange gains and exchange losses on financial receivables and liabilities are reported as financial items.Foreign exchange risk Foreign exchange risk is the risk that the fair value of or future cash flow from a financial instrument may vary due to changes in foreign exchange rates. Foreign exchange risk relates to the risk that fluctu-ations in exchange rates will have a negative impact on the group\u2019s P&L, balance sheet or cash flow.Transaction currency riskThe main exposure derives from the group\u2019s expenses in foreign currencies. This exposure is referred to as transaction exposure. The company'sdevelopment costs for C21 are mainly paid in EUR. As a result, the company is subject to exchange rate risks in relation to payment flows within Sweden and the eurozone, such as fluctuations where the exchange rate changes from the time an agreement is entered into until its payment is to be made in accordance with the agreement. Foreign exchange hedging is decided by the Board of Directors based on cash flow forecasts. In accordance with the company's policy for financial risk, the company exchanges EUR at a level of 60-100% of expected flows. See the table below for the level of exposure in each currency.Operating Operating incomeexpensesForeign exchange exposure 2022 (%)GBP - 8%EUR - 53%DKK - 3%USD - 5%SEK - 31%Foreign exchange exposure 2021 (%)GBP 100% 7%EUR - 52%DKK - 2%USD - 2%SEK - 37%Operating expenses in the table above are excluded from payroll expenses.As indicated in the table above, the group\u2019s main transaction exposure consists of EUR (EUR in 2020). A 10% stronger EUR against SEK would have a negative impact on the profit after tax and shareholders\u2019 equity by approximately 13,914 KSEK (14,191 KSEK).", "dimensions": { "concept": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-79-4": { "value": "CurrencyFunctional currency and reporting currencyFunctional currency is the currency in the primary economic environments in which the companies operate. The parent company\u2019s functional currency is the Swedish kronor, which is also the reporting currency for the parent company and the group. Unless otherwise stated, all amounts are rounded to the nearest thousand (KSEK).Foreign currency transactionsTransactions in foreign currency are translated to the functional currency at the exchange rate as on the transaction date. Monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rate on the balance sheet date. Exchangerate differences that arise are recognized in the profit/loss for the year. Exchange gains and exchange losses on operating receivables and operating liabilities are reported in operating results, while exchange gains and exchange losses on financial receivables and liabilities are reported as financial items.Foreign exchange risk Foreign exchange risk is the risk that the fair value of or future cash flow from a financial instrument may vary due to changes in foreign exchange rates. Foreign exchange risk relates to the risk that fluctu-ations in exchange rates will have a negative impact on the group\u2019s P&L, balance sheet or cash flow.Transaction currency riskThe main exposure derives from the group\u2019s expenses in foreign currencies. This exposure is referred to as transaction exposure. The company'sdevelopment costs for C21 are mainly paid in EUR. As a result, the company is subject to exchange rate risks in relation to payment flows within Sweden and the eurozone, such as fluctuations where the exchange rate changes from the time an agreement is entered into until its payment is to be made in accordance with the agreement. Foreign exchange hedging is decided by the Board of Directors based on cash flow forecasts. In accordance with the company's policy for financial risk, the company exchanges EUR at a level of 60-100% of expected flows. See the table below for the level of exposure in each currency.Operating Operating incomeexpensesForeign exchange exposure 2022 (%)GBP - 8%EUR - 53%DKK - 3%USD - 5%SEK - 31%Foreign exchange exposure 2021 (%)GBP 100% 7%EUR - 52%DKK - 2%USD - 2%SEK - 37%Operating expenses in the table above are excluded from payroll expenses.As indicated in the table above, the group\u2019s main transaction exposure consists of EUR (EUR in 2020). A 10% stronger EUR against SEK would have a negative impact on the profit after tax and shareholders\u2019 equity by approximately 13,914 KSEK (14,191 KSEK).", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-79-5": { "value": "CurrencyFunctional currency and reporting currencyFunctional currency is the currency in the primary economic environments in which the companies operate. The parent company\u2019s functional currency is the Swedish kronor, which is also the reporting currency for the parent company and the group. Unless otherwise stated, all amounts are rounded to the nearest thousand (KSEK).Foreign currency transactionsTransactions in foreign currency are translated to the functional currency at the exchange rate as on the transaction date. Monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rate on the balance sheet date. Exchangerate differences that arise are recognized in the profit/loss for the year. Exchange gains and exchange losses on operating receivables and operating liabilities are reported in operating results, while exchange gains and exchange losses on financial receivables and liabilities are reported as financial items.Foreign exchange risk Foreign exchange risk is the risk that the fair value of or future cash flow from a financial instrument may vary due to changes in foreign exchange rates. Foreign exchange risk relates to the risk that fluctu-ations in exchange rates will have a negative impact on the group\u2019s P&L, balance sheet or cash flow.Transaction currency riskThe main exposure derives from the group\u2019s expenses in foreign currencies. This exposure is referred to as transaction exposure. The company'sdevelopment costs for C21 are mainly paid in EUR. As a result, the company is subject to exchange rate risks in relation to payment flows within Sweden and the eurozone, such as fluctuations where the exchange rate changes from the time an agreement is entered into until its payment is to be made in accordance with the agreement. Foreign exchange hedging is decided by the Board of Directors based on cash flow forecasts. In accordance with the company's policy for financial risk, the company exchanges EUR at a level of 60-100% of expected flows. See the table below for the level of exposure in each currency.Operating Operating incomeexpensesForeign exchange exposure 2022 (%)GBP - 8%EUR - 53%DKK - 3%USD - 5%SEK - 31%Foreign exchange exposure 2021 (%)GBP 100% 7%EUR - 52%DKK - 2%USD - 2%SEK - 37%Operating expenses in the table above are excluded from payroll expenses.As indicated in the table above, the group\u2019s main transaction exposure consists of EUR (EUR in 2020). A 10% stronger EUR against SEK would have a negative impact on the profit after tax and shareholders\u2019 equity by approximately 13,914 KSEK (14,191 KSEK).", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-88-1": { "value": "Updated standards and interpretations from IASB and IFRIC interpretations that came into force during the 2022 calendar year have had no materialimpact on the group.", "dimensions": { "concept": "ifrs-full:ExplanationOfDepartureFromIFRS", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-88-2": { "value": "Updated standards and interpretations from IASB and IFRIC interpretations that came into force during the 2022 calendar year have had no materialimpact on the group.", "dimensions": { "concept": "ifrs-full:ExplanationOfFinancialEffectOfDepartureFromIFRS", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-126-3": { "value": "perating segmentsOperating segments are reported in a way that corresponds with internal reporting structures. The profit/loss generated by a business segment is then followed up by the company\u2019s chief operating decision maker, who is responsible for assessing the profit/loss figures and allocating resources to the business segment. In the group, this function is identified as the company\u2019s CEO.An operating segment is a component of the group that engages in business activities from which it may earn revenues and incur expenses, and for which discrete financial information is available. Vicore does not divide its business into different segments, instead it sees the entire business of the group as one segment. This followsthe company\u2019s internal organization and reporting structures.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-144-1": { "value": "ClassificationNon-current assets and non-current liabilities consist in all essentials solely of amounts that are than twelve months after the reporting period. Current assets and current liabilities consist in all essential solely of amounts that are expected to be recovered or settled within twelve months of the reporting period.", "dimensions": { "concept": "ifrs-full:DisclosureOfReclassificationsOrChangesInPresentationExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-152-2": { "value": "Revenue from contracts with customersThe group reports revenue when the group fulfils a performance obligation, i.e. when a promised prod-uct is delivered to the customer and the customer takes control of the product. Control of a perfor-mance obligation can be transferred over time or ata point in time. Revenue consists of the amount thecompany expects to receive as compensation for the transferred products or services. For the group to report revenue from contracts with customers, each customer contract is analyzed according to the five-step model included in the standard:Step 1: Identify a contract between at least two parties that consists of enforceable rights and obligations.Step 2: Identify the performance obligations in the contract.Step 3: Determine the transaction price, i.e. the amount of consideration that the company is expected to receive in exchange for the promised goods or services.Step 4: Allocate the transaction price over the identified performance obligations.Step 5: Recognize revenue when the performance obligations are satisfied, i.e. when control is transferred to the customer.The group\u2019s net sales are currently not a significant part of the business.", "dimensions": { "concept": "ifrs-full:DisclosureOfRevenueExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-152-3": { "value": "Revenue from contracts with customersThe group reports revenue when the group fulfils a performance obligation, i.e. when a promised prod-uct is delivered to the customer and the customer takes control of the product. Control of a perfor-mance obligation can be transferred over time or ata point in time. Revenue consists of the amount thecompany expects to receive as compensation for the transferred products or services. For the group to report revenue from contracts with customers, each customer contract is analyzed according to the five-step model included in the standard:Step 1: Identify a contract between at least two parties that consists of enforceable rights and obligations.Step 2: Identify the performance obligations in the contract.Step 3: Determine the transaction price, i.e. the amount of consideration that the company is expected to receive in exchange for the promised goods or services.Step 4: Allocate the transaction price over the identified performance obligations.Step 5: Recognize revenue when the performance obligations are satisfied, i.e. when control is transferred to the customer.The group\u2019s net sales are currently not a significant part of the business.", "dimensions": { "concept": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-180-3": { "value": "Government grantsGovernment grants are reported in the statement of financial position and the statement of comprehensive income when there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received. The grant is recognised as incomeover the period necessary to match them with the related costs, for which they are intended tocompensate, on a systematic basis.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-188-2": { "value": "Pension obligationsThe group only has defined contribution pension plans. In defined contribution plans, the group pays fixed contributions to a separate entity and has no legal or constructive obligation to pay further contributions if this entity does not have sufficient assets to pay all the remuneration to employees connected with the employees\u2019 service during the current or prior periods. Therefore, the group has no additional risk. For the group\u2019s obligations regarding contributions for defined contribution plans, these are reported as an expense in the consolidated profit/loss as the benefits are earned.Incentive programsThere are four types of share-based incentive programs in the group: two option programs for employees, and two share awards programs for certain board members. The option and share awards have been granted free of charge and are settled with equity instruments.The fair value of share-based payments is accounted for as personnel costs. The fair value of the employee stock options is determined at grant date with the Black-Scholes model for pricing of options. For the share awards, the fair value is determined at the time of allocation using a Monte Carlo simulation of future stock price development.The cost is reported, along with a corresponding increase in equity, during the period in which the vesting conditions are fulfilled, up to and including the date when the persons concerned are fully entitled to the compensation.The accumulated cost included in each reporting period shows to what extent the vesting period has been recognised with an estimate of the number of share-related instruments that eventually will be vested.Social security contributions attributable to share-related instruments to employees as compensation for purchased services must be expensed over the periods during which the services are performed. This cost must then be calculated using the same valuation model that was used whenEmployee benefitsShort-term remunerationShort-term remuneration to employees, such as salary, social security contributions, holiday pay and bonus, is expensed when the employees perform the services.the options were issued. The provision made shall be reassessed at each reporting date based on a calculation of the amount social charges that may be payable when the instruments are settled.", "dimensions": { "concept": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-188-4": { "value": "Pension obligationsThe group only has defined contribution pension plans. In defined contribution plans, the group pays fixed contributions to a separate entity and has no legal or constructive obligation to pay further contributions if this entity does not have sufficient assets to pay all the remuneration to employees connected with the employees\u2019 service during the current or prior periods. Therefore, the group has no additional risk. For the group\u2019s obligations regarding contributions for defined contribution plans, these are reported as an expense in the consolidated profit/loss as the benefits are earned.Incentive programsThere are four types of share-based incentive programs in the group: two option programs for employees, and two share awards programs for certain board members. The option and share awards have been granted free of charge and are settled with equity instruments.The fair value of share-based payments is accounted for as personnel costs. The fair value of the employee stock options is determined at grant date with the Black-Scholes model for pricing of options. For the share awards, the fair value is determined at the time of allocation using a Monte Carlo simulation of future stock price development.The cost is reported, along with a corresponding increase in equity, during the period in which the vesting conditions are fulfilled, up to and including the date when the persons concerned are fully entitled to the compensation.The accumulated cost included in each reporting period shows to what extent the vesting period has been recognised with an estimate of the number of share-related instruments that eventually will be vested.Social security contributions attributable to share-related instruments to employees as compensation for purchased services must be expensed over the periods during which the services are performed. This cost must then be calculated using the same valuation model that was used whenEmployee benefitsShort-term remunerationShort-term remuneration to employees, such as salary, social security contributions, holiday pay and bonus, is expensed when the employees perform the services.the options were issued. The provision made shall be reassessed at each reporting date based on a calculation of the amount social charges that may be payable when the instruments are settled.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-233-3": { "value": "Leasing agreementThe group\u2019s leasing portfolio consists of a fewoperating leases for premises, which are the two classes of leased assets presented by the group.The leasing agreements are reported as contract assets with a corresponding lease liability on the daythat the leased asset is available for use by the group.Short-term leases and low value leases are excluded.Each leasing payment is divided between amortiza-tion of the lease debt and financial cost. The financialcost shall be distributed over the lease period so thateach accounting period is charged with an amount corresponding to a fixed interest rate for the liabilityreported during each period.The leasing period is determined as the non-cancel-lable period together with both periods covered by an option to extend the lease if the lessee is reasonablysure to take advantage of that option, and periods covered by an opportunity to terminate the lease if thelessee is reasonably sure not to exercise that option.The group's leasing liabilities are recognized at the present value of the group's future leasing fees. Leasing payments have been discounted with thegroup's marginal loan interest rate.The group's contract assets are recognized at cost and initially include the present value of theleasing liabilities, adjusted for leasing fees paid onor before the commencement date and initial directexpenses. Recovery costs are included in the asset ifa corresponding provision regarding recovery costs has been identified. The contract asset is amortizedon a straight-line basis over the shorter of the asset'suseful life and the duration of the lease.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-277-3": { "value": "Financial incomeFinancial income consists of capital gains on and dividend incomes from financial fixed assets. Dividend income is recognized when the right to receive a dividend has been established.Exchange rate gains and losses are reported net.Financial costsFinancial costs consist mainly of interest expenseson loans. Exchange rate gains and losses are reported net.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-287-3": { "value": "Income taxesIncome taxes consist of current tax and deferred tax. Income taxes are recognized in profit or loss for the year, except when the underlying transac-tion is recognized in other comprehensive incomeor equity, in which case the tax effect is recognized in other comprehensive income or equity.Current taxCurrent tax is the tax that must be paid or received for the current year, with the application of the tax rates that have been decided, or in practice decided, on the balance sheet date. Current tax also includes adjustments to the current tax attributable to previous periods.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-301-3": { "value": "Earnings per shareEarnings per share before dilution are calculated as profit or loss attributable to the parent company shareholders divided by the weighted average number of ordinary shares outstanding during the period.Earnings per share after dilution are calculated as profit or loss attributable to the parent company shareholders divided, in some cases adjusted, by the sum of the weighted average number of ordinary shares and potential ordinary shares that may give rise to dilution effects. A dilution effect of potential ordinary shares is recognized only if a translation into ordinary shares would lead to a reduction of earnings per share after dilution.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-316-3": { "value": "Acquired intangible assetsIntangible assets in the group consist of patents, licenses and similar rights. They are valued at cost that is decreased by accumulated depreciation andany accumulated impairment losses.An intangible asset is recognized if it is probable that the asset will generate future economic benefits for the group, the criteria for capitalization are met and the costs can be measured reliably. An intangible asset is valued at cost when it is includedfor the first time in the financial report. Intangible assets with finite useful lives are reported at cost less depreciation and any impairment losses. Intangible fixed assets with finite useful lives are depreciated linearly over the asset\u2019s estimated useful life. Intangible assets with indefinite useful lives are instead tested annually for impairment.Intangible assets with finite and indefinite useful lives are reviewed for impairment requirements in cases where there are indications that a write-down may be needed. The useful life of intangible assets is reviewed at each balance sheet date and adjusted if necessary.Capitalization of development expenditureThe expenses that arise during the development phase are capitalized as intangible assets when, according to management\u2019s assessment, they are likely to result in future economic benefits for the group, the criteria for capitalization are met and the costs can be measured in a reliable way. Otherwise,development expenses are expensed as normal operating expenses.The group only has acquired intangible assets.Depreciation principlesDepreciation begins when the asset can be used, i.e. when it is in the place and in the condition required to be able to use it in the way managementintends. The estimated useful life for intangible fixed assets with a finite useful life is 5 years. Depre-ciation is made on a straight-line basis over theestimated useful life of the asset, which coincides with the remaining patent period for the product. Tangible fixed assetsTangible fixed assets are reported in the group at cost after deductions for accumulated deprecia-tion and any accumulated impairment losses. The cost includes the purchase price and any costs directly attributable to the asset to bring it in place and in condition to be utilized in accordance with the purpose of the acquisition.The carrying amount of an asset is derecognized from the balance sheet when disposing or divesting, or when no future economic benefits are expected from use or disposing/divesting of the asset. Gains or losses arising from the sale or disposal of an asset consist of the difference between the selling price and the asset\u2019s carrying amount with the deduction of direct sales costs. Gains and losses are reported as other operating income/expenses.Additional expensesAdditional expenses are added to the asset\u2019s carrying amount only if it is probable that the future economic benefits associated with the asset will be leveraged by the group and that the cost of the asset can be measured reliably. All other additional expenses are reported as an expense during the period they arise. Repairs are expensed on an ongoing basis.Depreciation principlesThe depreciable amount shall be allocated on a systematic basis over the asset\u2019s estimated useful life. Used depreciation methods, residual values and useful lives are reviewed at the end of each year.The estimated useful lives are:Equipment ...............................5 years", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForExpensesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-316-4": { "value": "Acquired intangible assetsIntangible assets in the group consist of patents, licenses and similar rights. They are valued at cost that is decreased by accumulated depreciation andany accumulated impairment losses.An intangible asset is recognized if it is probable that the asset will generate future economic benefits for the group, the criteria for capitalization are met and the costs can be measured reliably. An intangible asset is valued at cost when it is includedfor the first time in the financial report. Intangible assets with finite useful lives are reported at cost less depreciation and any impairment losses. Intangible fixed assets with finite useful lives are depreciated linearly over the asset\u2019s estimated useful life. Intangible assets with indefinite useful lives are instead tested annually for impairment.Intangible assets with finite and indefinite useful lives are reviewed for impairment requirements in cases where there are indications that a write-down may be needed. The useful life of intangible assets is reviewed at each balance sheet date and adjusted if necessary.Capitalization of development expenditureThe expenses that arise during the development phase are capitalized as intangible assets when, according to management\u2019s assessment, they are likely to result in future economic benefits for the group, the criteria for capitalization are met and the costs can be measured in a reliable way. Otherwise,development expenses are expensed as normal operating expenses.The group only has acquired intangible assets.Depreciation principlesDepreciation begins when the asset can be used, i.e. when it is in the place and in the condition required to be able to use it in the way managementintends. The estimated useful life for intangible fixed assets with a finite useful life is 5 years. Depre-ciation is made on a straight-line basis over theestimated useful life of the asset, which coincides with the remaining patent period for the product. Tangible fixed assetsTangible fixed assets are reported in the group at cost after deductions for accumulated deprecia-tion and any accumulated impairment losses. The cost includes the purchase price and any costs directly attributable to the asset to bring it in place and in condition to be utilized in accordance with the purpose of the acquisition.The carrying amount of an asset is derecognized from the balance sheet when disposing or divesting, or when no future economic benefits are expected from use or disposing/divesting of the asset. Gains or losses arising from the sale or disposal of an asset consist of the difference between the selling price and the asset\u2019s carrying amount with the deduction of direct sales costs. Gains and losses are reported as other operating income/expenses.Additional expensesAdditional expenses are added to the asset\u2019s carrying amount only if it is probable that the future economic benefits associated with the asset will be leveraged by the group and that the cost of the asset can be measured reliably. All other additional expenses are reported as an expense during the period they arise. Repairs are expensed on an ongoing basis.Depreciation principlesThe depreciable amount shall be allocated on a systematic basis over the asset\u2019s estimated useful life. Used depreciation methods, residual values and useful lives are reviewed at the end of each year.The estimated useful lives are:Equipment ...............................5 years", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForDepreciationExpenseExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-394-3": { "value": "Impairment of non-financial assetsThe group\u2019s reported assets are assessed in cases where there are indications of a decline in value of tangible or intangible assets, i.e. whenever events or changes in circumstances indicate that the fair value is not recoverable. Furthermore, the group\u2019s development projects are reviewed annually for impairment requirements until they are available for use. This is done regardless of whether there are indications of a decline in value or not.An impairment is recognized when an asset\u2019s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of the asset\u2019s fair value less the cost of sale on the one hand and the value in use on the other. When assessing impairment, assets are grouped at the lowest level where there are separate identifiable cashflows (cash-generating units). When the need for impairment has been identified for a cash-gener-ating unit (group of units), the impairment amount is distributed proportionally among the assets included in the cash-generating unit (group of units).A previously recognized impairment is reversed if the recovery amount is deemed to exceed thefair value. Reversal does not occur with an amount that is greater than what the fair value would have been recorded to if the impairment had not been recognized in previous periods. Any reversals arereported in the income statement.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-424-3": { "value": "Financial assets and liabilitiesA financial asset or financial liability is recognized in the balance sheet when the group becomes a party according to the instrument\u2019s contractualterms. A financial asset is removed from thebalance sheet when the rights in the agreement are realized, expire or when the group loses control over them. The same applies to a part of a financial asset. A financial liability is removed from the balance sheet when the obligation in the agreement is fulfilled or otherwise extinguished. The same applies to a part of a financial debt.Acquisitions and divestments of financial assets are reported on the trade date. The trade date constitutes the day when the company undertakes to acquire or divest the asset.Financial instruments are classified on initial recognition, including on the basis of what purpose the instrument was acquired and man-aged. This classification determines the valuation Classification and valuation of financial assetsThe classification of financial assets that are debt instruments, is based on the group\u2019s business model for managing the asset and the nature of theasset\u2019s contractual cash flows.Assets are classified according to:Amortized costFair value through profit or loss, orFair value through other comprehensive incomeThe group\u2019s financial assets that are classified at amortized cost include accounts receivable, certain other receivables, short-term investments, and cash and cash equivalents. Financial assets classified at amortised cost are initially measured at fair value with the addition of transaction costs. After initial recognition, the assets are valued at amortized cost after a deduction of a loss reserve for expected credit losses. Assets classified at amortized cost are held according to the business model to collect contractual cash flows, which are solely payments of principal and interest on the outstanding principal amount.The group\u2019s financial assets that are classified at fair value through profit or loss relate to holdings in listed and non-listed shares.Impairment of financial assetsThe group\u2019s impairment model is based on expected credit losses, and takes into account prospective information. A loss reserve is made when there is an exposure to credit risk, usually at initial recognition for an asset or receivable. Classification and valuation of financial liabilitiesThe group\u2019s financial liabilities consist of accounts payable and other current liabilities, which are allclassified at amortized cost. Financial liabilities recognized at amortized cost are initially measuredat fair value including transaction costs. After the initial recognition, they are valued according to the effective interest method.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-484-3": { "value": "Cash and cash equivalentsCash and cash equivalents consist of cash and balances as well as immediately available credit balances with banks and corresponding financial institutions.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-489-2": { "value": "EquityAll shares in the company are ordinary shares, which are reported as equity. The share capital is reported up to its quota value and any excess part is reported as Other contributed capital. Transaction costs, directly attributable to the issue of new ordinary shares or options, are reported, net after tax, in equity as a deduction from the issue proceeds.Note 24 Shareholders\u2019 equityShare capital and other contributed capitalNumber of Other contributed SEKordinary shares Share capitalcapitalAt January 1, 2021 60,418,239 30,209,119 702,052,950Issue in kind, November 2, 2020, registered February 142,054 71,027 2,928,97322, 2021New share issue, February 22, 2021, registered March 11,200,000 5,600,000 312,821,8959, 2021Share-based payments 0 0 3,861,698At December 31, 2021 71,760,293 35,880,146 1,021,665,516At January 1, 2022 71,760,293 35,880,146 1,021,665,516New share issue, June 17, 2022, registered June 28, 87,686 43,843 2,956,1572022New share issue, December 8, 2022, registered Decem-10,000,000 5,000,000 182,292,382ber 28, 2022Share-based payments 0 0 3,897,141At December 31, 2022 81,847,979 40,923,989 1,210,811,196", "dimensions": { "concept": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-498-3": { "value": "Contingent liabilitiesA contingent liability is recognised when there is a possible commitment that arises from past events and whose existence is confirmed only by one or more uncertain future events, or when there is a commitment that is not reported as a liability or provision due to it being unlikely that an outflow of resources will be required.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-506-3": { "value": "Cash flowCash and cash equivalents consist of available cash, bank credit balances and other liquid investments with an original maturity of less than three months, which are exposed to insignificant value fluctuation. Incoming and outgoing payments are reported in the cash flow statement. The cash flow statement has been prepared in accordance with the indirect method.", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForCashFlowsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-515-2": { "value": "Note 2 Judgements and accounting estimatesThe preparation of the financial statements in accordance with IFRS requires company man-agement to make judgements and accounting estimates that affect the application of the accounting policies and the carrying amounts of assets, liabilities, revenue and expenses. The actualoutcome could deviate from these estimates.The accounting estimates and assumptions are evaluated continuously. Changes to the accounting estimates are recognized in the period in which the change is made if the change only has affected the period, or in the period in which the change is made and future periods if the change affects both the current period and future periods.Sources of uncertainty in the accounting estimatesThe sources of uncertainty in the accounting estimates, entailing a significant risk that the value of assets or liabilities might need to be adjusted to a material extent during the forthcoming fiscal year,include impairment testing of intangible assets with indefinite useful lives.Impairment testing of intangible assetsWhen impairment testing intangible assets, a num-ber of significant assumptions and judgements must be taken into account in order to calculate a recoverable amount. These assumptions and judgements relate to, among others, future expected selling price for the company\u2019s products C21, IMiD and C106, expected market penetration, expected development-, sales and marketing costs and expected likelihood that the products will pass the remaining stages of development. The assumptions are based on industry- and market-specific data and are produced by the man-agement and reviewed by the Board of Directors. For more information about impairment testing, see Note 15 \"Patent, licenses and similar rights\".Other judgments and accounting estimatesCapitalization of intangible assetsDevelopment expenditures are capitalized when they fulfill the criteria set out in IAS 38 and are expected to represent material amounts for the development initiative as a whole. Development expenditures are otherwise expensed as normal operating costs. The most important criteria for capitalization are that the end product of the development work has a demonstrable future earning capacity or cost savings and cash flow, andthat there are technical and financial preconditions to finish the development work when it begins. The group only has acquired intangible assets. Since regulatory approval has not yet been obtained, no costs have been capitalized.Research and development expenses The company conducts research and developmentwith external collaboration partners, such as clinical research organizations (CROs). The company estimate the timing of the costs when the project commences. This cost is then used as abasis for settlement with the external collaboration partner. An evaluation and update of the calculationis performed monthly and forms the basis for booking accrued costs attributable to research and development.Incentive programsThe group has four active share-based long-termincentive programs. The applicable accounting poli-cies are described in Note 1 \"Accounting principles\". The cost for the remuneration that is recognized in a period is dependent on the original valuation that was made on the contract date of with the holder of the option/share award, the number of months of service required by the participant for becoming entitled to options (accruals are made over thisperiod), the number of options that are expected to be vested by the participant under the terms of the programs and a continuous reassessment of the value of the tax benefits for the participants in the incentive programs (for determining provisions for social security contributions). Those estimates which affect the cost in a period and the corre-sponding increase in equity mainly refer to inputs for the valuation of the options. The models used for this purpose are the Black & Scholes model and a Monte Carlo simulation. Significant assumptions in these valuations are described in Note 8 \"Share-based payments\".Tax loss carryforwardsThe group\u2019s tax loss carryforwards have not been measured and are not recognized as a deferred tax asset. These tax loss carryforwards will be measured valued only when the group has established a level of earnings which management with confidence estimate will lead to taxable profits.", "dimensions": { "concept": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-609-2": { "value": "Not 3 Operating segmentsVicore does not divide its business into different operating segments. Instead the group\u2019s entire business is treated as one operating segment. This reflects the company\u2019s internal organisation and reporting sys-tem. Vicore\u2019s chief operating decision maker is the CEO. Currently, Vicore is operating mainly in Sweden, where the group\u2019s tangible and intangible fixed assets are attributed.", "dimensions": { "concept": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-614-2": { "value": "Note 4 Operating expenses by nature of expenseThe total expenses classified by function are distributed in the following cost categories:2022 2021Other external expenses 224,713 256,517Personnel expenses 59,169 33,304Depreciation and amortization 3,612 3,598Other operating expenses 4,784 2,492Total 292,278 295,911", "dimensions": { "concept": "ifrs-full:DisclosureOfExpensesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-614-3": { "value": "Note 4 Operating expenses by nature of expenseThe total expenses classified by function are distributed in the following cost categories:2022 2021Other external expenses 224,713 256,517Personnel expenses 59,169 33,304Depreciation and amortization 3,612 3,598Other operating expenses 4,784 2,492Total 292,278 295,911", "dimensions": { "concept": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-614-4": { "value": "Note 4 Operating expenses by nature of expenseThe total expenses classified by function are distributed in the following cost categories:2022 2021Other external expenses 224,713 256,517Personnel expenses 59,169 33,304Depreciation and amortization 3,612 3,598Other operating expenses 4,784 2,492Total 292,278 295,911", "dimensions": { "concept": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-614-5": { "value": "Note 4 Operating expenses by nature of expenseThe total expenses classified by function are distributed in the following cost categories:2022 2021Other external expenses 224,713 256,517Personnel expenses 59,169 33,304Depreciation and amortization 3,612 3,598Other operating expenses 4,784 2,492Total 292,278 295,911", "dimensions": { "concept": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-614-6": { "value": "Note 4 Operating expenses by nature of expenseThe total expenses classified by function are distributed in the following cost categories:2022 2021Other external expenses 224,713 256,517Personnel expenses 59,169 33,304Depreciation and amortization 3,612 3,598Other operating expenses 4,784 2,492Total 292,278 295,911Note 10 Other operating expenses2022 2021Exchange rate losses 4,784 2,492Total other operating expenses 4,784 2,492", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-614-7": { "value": "Note 4 Operating expenses by nature of expenseThe total expenses classified by function are distributed in the following cost categories:2022 2021Other external expenses 224,713 256,517Personnel expenses 59,169 33,304Depreciation and amortization 3,612 3,598Other operating expenses 4,784 2,492Total 292,278 295,911", "dimensions": { "concept": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-615-2": { "value": "Note 5 Audit feesErnst & Young AB 2022 2021Audit fees* 435 450Other audit related services 170 92Tax consultancy services 0 0Other services 0 10Total 605 552* Audit engagement refers to fees for the statutory audit, i.e. work that has been necessary to produce the auditor\u2019s report as well as audit advisory services provided in connection with the audit engagement.", "dimensions": { "concept": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-616-2": { "value": "Note 6 Leases 2022 2021 Dec 31Dec 31Contract assetsPremises 63 317Total 63 317Contract liabilitiesLong-term 0 320Short-term 65 0Total 65 320The following amounts related to leasing contracts are reported 2022 2021 in the consolidated statement of comprehensive income:Leasing fees, short-term 1,184 1,066DepreciationPremises 255 239Interest 4 6Total 1,443 1,311The total cash flow related to leasing agreements was 259 KSEK (245 KSEK) for 2022. For information on the maturity of leases, see Note 19 \"Financial risks\".", "dimensions": { "concept": "ifrs-full:DisclosureOfLeasesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-617-2": { "value": "Note 7 Employees and personnel costsAverage number of 2022 2021employeesNo. of of which men/ No. of of which men/ employeeswomenemployeeswomenParent company 5 60%/40% 4 50%/50%Subsidiaries 16 19%/81% 12 30%/70%Group total 21 29%/71% 16 36%/64%Personnel costs for the Board of Directors, senior executives and other employees 2022 2021GroupThe Board and other senior executivesSalaries and other remuneration 25,393 17,898Social security contributions 6,336 -120Pension costs 4,527 3,04636,256 20,824GroupOther employeesSalaries and other remuneration 15,406 9,048Social security contributions 3,529 744Pension costs 2,181 2,23921,116 12,031GroupOther personnel costs 1,797 4491,797 449Total personnel costs 59,169 33,304Parent companyThe Board and other senior executivesSalaries and other remuneration 12,063 9,813Social security contributions 3,339 -2,154Pension costs 2,210 1,50817,612 9,167Parent companyOther employeesSalaries and other remuneration 874 906Social security contributions 262 277Pension costs 143 721,279 1,255Parent companyOther personnel costs 779 226779 226Total personnel costs 19,670 10,648Senior executives include members of the Board of Directors, the CEO and other senior executives.Salaries and other remunerationCosts related to the long-term incentive programs amounts to 3,897 KSEK (3,862 KSEK) of the payroll expenses and 975 KSEK (-5,425 KSEK) of the social security contributions. PensionsAll pension plans in the group are defined contribution plans. The group\u2019s total cost for defined contribution plans amounted to 6,709 KSEK (5,285 KSEK). Gender breakdown among senior executives2022\ue878 2021\ue878 Dec 31Dec 31GroupProportion of women on the Board 40% 33%Proportion of men on the Board 60% 67%Proportion of women among other senior executives 50% 50%Proportion of men among other senior executives 50% 50%Parent companyProportion of women among other senior executives 25% 25%Proportion of men among other senior executives 75% 75%Information regarding remuneration to the Board and other senior executivesBasic Share- Other salary, Pension Variable based remunera-2022board fee*costsremunerationpaymentstion* TotalChairman of the BoardJacob Gunterberg 438 0 0 0 637 1,075Members of the BoardHans Schikan 175 0 0 91 275 541Maarten Kraan 175 0 0 91 275 541Sara Malcus 175 0 0 91 275 541Heidi Hunter 175 0 0 170 275 620Senior executivesCEO 2,738 809 821 613 0 4,981Other senior executives** 13,326 3,718 3,263 2,597 0 22,904Total 17,202 4,527 4,084 3,653 1,737 31,203* Board fees as resolved at the AGM, excluding social security contributions and remuneration of board committee work for the May 2022 to May 2023 financial year. Other remuneration include remuneration for board committee work. Other remuneration also includes the additional board fee decided by the general meeting, which was conditional on the acquisition of shares in the company. ** For more information, see \"Remuneration for senior executives\" below.Basic Share- Other salary, Pension Variable based remunera-2021board fee*costsremunerationpaymentstion* TotalChairman of the BoardMichael Wolff Jensen 450 0 0 730 50 1,230Members of the BoardJacob Gunterberg 150 0 0 0 125 275Hans Schikan 150 0 0 142 50 342Maarten Kraan 150 0 0 142 75 367Sara Malcus 150 0 0 108 50 308Heidi Hunter 150 0 0 365 50 565Senior executivesCEO 2,753 745 261 431 0 4,190Other senior executives** 9,484 2,301 753 1,287 0 13,825Total 13,437 3,046 1,014 3,205 400 21,102* Board fees as resolved at the AGM, excluding social security contributions and remuneration of board committee work for the May 2021 to May 2022 financial year. Other remuneration include remuneration for board committee work. ** For more information, see \"Remuneration for senior executives\" below.Share-based paymentsShare-based payments refer to share awards and options granted to independent directors, the CEO, other senior executives, and other employees. Each vested share award entitles the holder to receive one share in the company, provided that the holder is still a member of the Board of Directors of the company at the relevant time of vesting. Each option entitles the holder to acquire one share in the company for a predetermined exercise price. The options are subject to vesting over a three year period whereby all options shall be vested on the third anniversary of the granting date, provided that the holder, with some customary exceptions is still employed by the company. The participants in the programs have received the share awards / options free of charge. For further information about the incentive programs, see Note 8 \"Share-based payments\".Other remunerationOther remuneration include remuneration for board committee work. For the fiscal year 2022, other remu-neration also includes the additional board fee decided by the general meeting, which was conditional on the acquisition of shares in the company. Remuneration for senior executivesRemuneration of the CEO and other senior executives consists of, in accordance with the guidelines for remuneration decided by the shareholder's meeting in 2021, basic salary, pension benefits, bonus and share-based incentives adopted by the shareholders\u2019 meeting (e.g. employee stock options). Other senior executives refer to the individuals who, together with the CEO, constitute the group management. As of January 1, 2021, other senior executives refer to the Chief Financial Officer, Chief Medical Officer, Chief Scientific Officer, VP Clinical Development, Program Director, early development, and Chief Administrative Officer. During 2021, the group of other senior executives was expanded as follows: Head of Digital Therapeutics (July 1, 2021), Chief Commercial Officer (October 2, 2021) and Head of Business Develop-ment (November 8, 2021).The CEO has a period of notice of six months in the event the termination is made by the group or if the CEO resigns. Other senior executives have a period of notice of three to six months, in the event the termination is made by the group or if the senior executive resigns.In addition to salary during the termination period, the CEO is entitled to a termination benefit corresponding of six months\u2019 salary in the event of termination by the company on a basis other than a breach of contract.", "dimensions": { "concept": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-622-2": { "value": "Note 8 Share-based paymentsThe purpose of share-based incentive programs is to promote the company\u2019s long-term interests by motivating and rewarding the company\u2019s senior management and other co-workers in line with the interests of the shareholders. As of December 31, 2022, Vicore has four active incentive programs that include the management team, other employees and certain board members. Assuming full utilization and maximum goal achievement of all granted employee stock options and share awards as of December 31, 2022, corresponding to 2,988,489 shares, would entail a dilution of 3.5 percent. Taking into account also non-granted employee stock options and warrants that may be used as hedge for social security contributions, the maximum dilution as of December 31, 2022, amounts to 5.6 percent.Long-term incentive program 2018The Extra General Meeting in Vicore held on August 13, 2018, resolved, in accordance with the Board of Directors\u2019 proposal, to adopt a long-term incentive program for certain of the company\u2019s senior manage-ment and key persons (\u201cCo-worker LTIP 2018\u201d) in Vicore. A maximum of 2,000,000 options (Co-worker LTIP 2018) may be allotted to participants under the program. Of these, a total of 1,325,800 options and 475,000 share awards have been allocated. The increase in the company\u2019s share capital in full utilization of the incentive program amounts to a maximum of approximately SEK 1,000,000, corresponding to a dilution of approximately 2.4 percent of the total number of shares. The options have been granted to the participants of the incentive programs free of charge and the settlement is made with equity instruments.Co-worker LTIP 2018Co-worker LTIP 2018 is an incentive program intended for members of senior management and key persons in the company. According to the program participants will be granted, free of charge, options subject to three year vesting that entitle to acquire a maximum of 2,000,000 shares in the company in total, in accordance with the terms stipulated below.The Board of Directors of the company believes that an equity-based incentive program is a central part of an attractive and competitive remuneration package in order to attract, retain and motivate competent mem-bers of senior management and key persons in the company, and to focus the participants on delivering exceptional performance which contributes to value creation for all shareholders.Co-worker LTIP 2018 is an incentive program under which the participants will be granted options free of charge. The Board of Directors shall resolve upon the allocation of options annually or at such time as the Board of Directors can be considered as relevant to such decision (with each respective date of granting being a \u201cgranting date\u201d). Each option entitles the holder to acquire one share in the company for a predetermined exercise price. The exercise price per share shall correspond to 150 percent of the volume weighted average price of the company\u2019s share for the five trading days preceding the granting date. The options are subject to vesting over a three year period whereby all options shall be vested on the third anniversary of the granting date, provided that the holder, with some customary exceptions is still employed by the company. The latest point in time at which vested options may be exercised shall be the fourth anniversary of the granting date.The options are valued according to the so-called Black & Scholes model, which means that the value of the options depends, among other things, on the value of the underlying share, the options\u2019s issue price and life, risk-free interest rate and volatility. The volatility has been based on the expected volatility of the Vicore share and other listed companies with similar operations. The risk-free interest rate was equated with the interest rate for Swedish govern-ment bonds. The fair value of the options at the time of allocation during 2020 amounts to SEK 3.98 per option. No allocation within Co-worker LTIP 2018 has taken place in 2021 or 2022. For further information about inputs that have been used in the model, see the Annual Reports for the years 2018-2021.Long-term incentive program 2020The Annual General Meeting in Vicore Pharma Holding AB held on May 20, 2020, resolved, in accordance with the proposal from the Nomination Committee, to adopt a long-term incentive program for the new members of the Board of Directors (\u201cBoard LTIP 2020\u201d) in Vicore Pharma Holding AB. A maximum of 525,000 share awards may be allotted to participants in the program Board LTIP 2020. The increase in the company\u2019s share capital, assuming full utilization, amounts to a maximum of approximately SEK 262,500, corresponding to a dilution of 0.6% of the total number of shares.Board LTIP 2020Board LTIP 2020 is a program under which the participants will be granted, free of charge, share awards subject to performance vesting (\u201cshare awards\u201d) that entitle to shares in the company to be calculated in accordance with the principles stipulated below, however a maximum of 525,000 shares. Board LTIP 2020 is intended for the newly elected, main owner independent, members of the Board of Directors in the company. The Nomi-nation Committee believes that an equity-based incentive program is a central part of a competitive remuneration package in order to attract, retain and motivate internationally competent members of the Board of Directors, and to focus the partici-pants on delivering exceptional performance which contributes to value creation for all shareholders.The share awards shall vest gradually over approximately three years, corresponding to three terms up to the date of, whichever is earliest, (i) the Annual General Meeting 2023 or (ii) June 1, 2023 (\u201dvesting date\u201d), where each term equals the period from one Annual General Meeting up until the day falling immediately prior to the next Annual General Meeting or the vesting date, as applicable (each such period a \u201cterm\u201d). The share awards shall vest by 1/3 at the end of each term, provided that the participant is still a member of the Board of Directors of the company on said date. In addition to the vesting conditions just stated, the share awards are subject to performance vesting based on the development of the company\u2019s share price, in accordance with the vesting conditions below.The share awards are subject to performance vesting based on the development of the compa-ny\u2019s share price over the period from the date the share awards are allocated (\u201dgrant date\u201d) up to and including the vesting date. The development of the share price will be measured based on the volume weighted average price of the company\u2019s share on Nasdaq Stockholm for the 30 trading days immediately following the grant date and the 30 trading days immediately preceding the vesting date, respectively. In the event the price of the com-pany\u2019s share has thereby increased by more than 150 percent, 100 percent of the share awards shall vest, and should the share price have increased by 50 percent, 25 percent of the share awards shall vest. In the event of an increase of the share price between 50 and 150 percent, vesting of the share awards will occur linearly. Should the increase of the share price be less than 50 percent, no vesting will occur. The earliest point in time at which vested share awards may be exercised shall be the day falling immediately after the vesting date.The valuation of the share awards is based on a Monte Carlo simulation in accordance with accepted valuation theory. Volatility has been based on the expected volatility of the Vicore share and other listed companies with similar operations. The risk-free interest rate has been derived through an interpolation between a 2-year and 5-year government bond, respectively. The fair value of the share awards at the time of allocation amounts to SEK 5.18 per share award. In order to calculate the value of the share awards in relation to the current performance conditions, a starting value is used that corresponds to the volume-weighted average price paid for the Vicore share over a fixed period, which in this case corresponds to the value of the underlying share at the time of valuation.Long-term incentive programs 2021 The Annual General Meeting in Vicore Pharma Holding AB held on May 11, 2021, resolved to implement a long-term incentive program for sen-ior management and key persons in the company (\u201cCo-worker LTIP 2021\u201d) and to implement a long-term performance-based incentive program for independent board members in the company who are not participants in Board LTIP 2020 (\u201cBoard LTIP 2021\u201d). A maximum of 3,000,000 options (Co-worker LTIP 2021) and 61,773 share awards (Board LTIP 2021) may be allotted to participants in the programs. The increase in the company\u2019s share capital, assuming full utilization of both incentive programs, amounts to a maximum of approximately SEK 1,530,887, corresponding to a dilution of approximately 3.6 percent of the total number of shares.Board LTIP 2021Board LTIP 2021 is a program under which the participants will be granted, free of charge, share awards subject to performance vesting that entitle to shares in the company to be calculated in accordance with the principles stipulated below, however a maximum of 61,773 shares. Board LTIP 2021 is intended for independent board members in the company who are not participants in Board LTIP 2020. The Nomination Committee believes that an equity-based incentive program is a central part of a competitive remuneration package in order to attract, retain and motivate internationally competent members of the Board of Directors, and to focus the partici-pants on delivering exceptional performance which contributes to value creation for all shareholders.The share awards shall vest gradually over approximately three years, corresponding to three terms up to the date of, whichever is earliest, (i) the Annual General Meeting 2024 or (ii) June 1, 2024 (\u201dvesting date\u201d), where each term equals the period from one Annual General Meeting up until the day falling immediately prior to the next Annual General Meeting or the vesting date, as applicable (each such period a \u201cterm\u201d). The share awards shall vest by 1/3 at the end of each term, provided that the participant is still a member of the Board of Directors of the company on said date. In addition to the vesting conditions just stated, the share awards are subject to performance vesting based on the development of the company\u2019s share price, in accordance with the vesting conditions below.The share awards are subject to performance vesting based on the development of the compa-ny\u2019s share price over the period from the date the share awards are allocated (\u201dgrant date\u201d) up to and including the vesting date. The development of the share price will be measured based on the volume weighted average price of the company\u2019s share on Nasdaq Stockholm for the 30 trading days immediately following the grant date and the 30 trading days immediately preceding the vesting date, respectively. In the event the price of the com-pany\u2019s share has thereby increased by more than 80 percent, 100 percent of the share awards shall vest, and should the share price have increased by 40 percent, 25 percent of the share awards shall vest. In the event of an increase of the share price between 40 and 80 percent, vesting of the share awards will occur linearly. Should the increase of the share price be less than 40 percent, no vesting will occur. The earliest point in time at which vested share awards may be exercised shall be the day falling immediately after the vesting date.The valuation of the share awards is based on a Monte Carlo simulation in accordance with accepted valuation theory. Volatility has been based on the expected volatility of the Vicore share and other listed companies with similar operations. The risk-free interest rate has been derived through an interpolation between a 2-year and 5-year government bond, respectively. The fair value of the share awards at the time of allocation amounts to SEK 10.99 per share award. In order to calculate the value of the share awards in relation to the current performance conditions, a starting value is used that corresponds to the volume-weighted average price paid for the Vicore share over a fixed period, which in this case corresponds to the value of the underlying share at the time of valuation.Co-worker LTIP 2021Co-worker LTIP 2021 is an incentive program intended for members of senior management and key persons in the company. According to the program participants will be granted, free of charge, options subject to three-year vesting that entitle to acquire a maximum of 3,000,000 shares in the company in total.The Board of Directors of the company believes that Co-worker LTIP 2021 will create a strong alignment of the interests of the participants and the interests of the shareholders. Co-worker LTIP 2021 is adapted to the current position and needs of the company. The Board of Directors is of the opinion that Co-worker LTIP 2021 will increase and strengthen the participants\u2019 dedication to the company\u2019s operations, improve company loyalty and that Co-worker LTIP 2021 will be beneficial to both the shareholders and the company. Co-worker LTIP 2021 is a program under which the participants will be granted, free of charge, options. The Board of Directors shall annually resolve upon the allocation of options no later than the day falling three years after the Annual General Meeting 2021 (with each respective date of granting being a \u201cgrant date\u201d). Each Option entitles the holder to acquire one share in the company for a pre-determined exercise price. The exercise price shall correspond to 125 percent of the volume weighted average price of the company\u2019s share on Nasdaq Stockholm for the five trading days preceding the grantdate. The options shall vest over a three-year period with one third each year on the anniversary of the grant day, whereby all options shall vest on the third anni-versary of the grant date, provided that the holder, with some customary exceptions, still is employed by the company. The latest point in time at which vested options may be exercised shall be the fifth anniversary of the grant date.The options are valued according to the so-called Black & Scholes model, which means that the value of the options depends, among other things, on the value of the underlying share, the options\u2019s issue price and life, risk-free interest rate and volatility. The volatility has been based on the expected vola-tility of the Vicore share and other listed companies with similar operations. The risk-free interest rate was equated with the interest rate for Swedish government bonds. The fair value of the options at the time of allocation during 2021 amounts to SEK 8.45 per option. The following inputs have been used in the model:2022 2021Underlying share price 22.00 SEK 20.00 SEKExcercise price 28.75 SEK 26.48 SEKExpected volatility 50.00 % 50.00 %Option life 5 \u00e5r 5 \u00e5rExpected dividends 0 SEK 0 SEKRisk-free interest rate 2.56 % 0.10 %Summary of issued share awards and options2022 2021Average Number Average Number Issued share awards (Board LTIP exercise price of share exercise price of share 2018)per share awardawardsper share awardawardsAt January 1 0 0 0 433,333Forfeited/expired during the year 0 0 0 -433,333At December 31 0 0 0 0A total of 433,333 share awards expired during 2021.2022 2021Average Number Average Number Issued share awards (Board LTIP exercise price of share exercise price of share 2020)per share awardawardsper share awardawardsAt January 1 0 525,000 0 525,000Granted during the year 0 0 0 0Forfeited/expired during the year 0 -291,667 0 0At December 31 0 233,333 0 525,000A total of 291,667 share awards were forfeited during the year.2022 2021Average Number Average Number Issued share awards (Board LTIP exercise price of share exercise price of share 2021)per share awardawardsper share awardawardsAt January 1 0 61,773 0 0Granted during the year 0 0 0 61,773At December 31 0 61,773 0 61,773No share awards have been exercised, forfeited or expired during the year.2022 2021Average Average Issued options (Co-worker LTIP exercise price Number of exercise price Number of 2018)per option optionsper option optionsAt January 1 27.48 1,239,600 27.48 1,239,600Granted during the year 0 0 0 0Forfeited/expired during the year 25.49 -300,000 0 0At December 31 27.99 939,600 27.48 1,239,600A total of 300,000 options were forfeited/expired during the year.2022 2021Average Average Issued options (Co-worker LTIP exercise price Number of exercise price Number of 2021)per option optionsper option optionsAt January 1 26.26 807,600 0 0Granted during the year 28,72 987,850 26.26 807,600Forfeited during the year 27.84 -41,667 0 0At December 31 27.64 1,753,783 26.26 807,600A total of 41,667 options were forfeited during the year.Outstanding share awards and options at year-endDec 31, 2022 Dec 31, 2021Date of Exercise Share awards/Vested Share awards/Vested Program per yearexpirationpriceoptions (%)options (%)Annual Gen-Program share awards eral Meeting 0 233,333 88% 525,000 78%(Board LTIP 2020)2023Annual Gen-Program share awards eral Meeting 0 61,773 75% 61,773 38%(Board LTIP 2021)2024Program 2018 options September 27, 25.26 - - 283,333 100%(Co-worker LTIP 2018)2022Program 2019 options September 27, 26.17 396,267 100% 396,267 92%(Co-worker LTIP 2018)2023Program 2020 options September 24, 29.31 543,333 92% 560,000 68%(Co-worker LTIP 2018)2024Program 2021 options September 16, 26.26 765,933 68% 807,600 15%(Co-worker LTIP 2021)2026Program 2022 options September 27, 28.72 987,850 16% - -(Co-worker LTIP 2021)2027The costs for social security contributions related to share-based incentive programs varies from quarter to quarter due to the change in the underlying share price. Related provisions are reported as non-current liabilities. Total IFRS 2-classified payroll expenses for the incentive programs for the entire duration of the programs amount to 18,967 KSEK. The total costs for the share-based incentive programs for each year is presented below. These costs have had no cash impact. Summary of the total cost of the incentive programs 2022 2021IFRS 2-classified payroll expenses 3,897 3,862Provisions for social security contributions 975 -5,425Total 4,872 -1,563Summary of allotted options and share awards2022 2021Program 2018 Number Number Number Number share awards outstanding outstanding outstanding outstanding (Board LTIP at Jan 1, Granted/at Dec 31, at Jan 1, Granted/at Dec 31, 2018)2022forfeited20222021forfeited2021Former chairman of the Board Leif 0 0 0 83,333 -83,333 0DarnerMember of the 0 0 0 125,000 -125,000 0Board Hans SchikanMember of the Board Maarten 0 0 0 125,000 -125,000 0KraanFormer member of the Board Peter 0 0 0 50,000 -50,000 0Str\u00f6mMember of the 0 0 0 50,000 -50,000 0Board Sara MalcusTotal 0 0 0 433,333 -433,333 02022 2021Program 2020 Number Number Number Number share awards outstanding outstanding outstanding outstanding (Board LTIP at Jan 1, Granted/at Dec 31, at Jan 1, Granted/at Dec 31, 2020)2022forfeited20222021forfeited2021Former chairman of the Board Michael 350,000 -233,333 116,667 350,000 0 350,000Wolff JensenMember of the 175,000 -58,333 116,667 175,000 0 175,000Board Heidi HunterTotal 525,000 -291,667 233,333 525,000 0 525,0002022 2021Program 2021 Number Number Number Number share awards outstanding outstanding outstanding outstanding (Board LTIP at Jan 1, Granted/at Dec 31, at Jan 1, Granted/at Dec 31, 2021)2022forfeited20222021forfeited2021Member of the 20,591 0 20,591 0 20,591 20,591Board Hans SchikanMember of the Board Maarten 20,591 0 20,591 0 20,591 20,591KraanMember of the 20,591 0 20,591 0 20,591 20,591Board Sara MalcusTotal 61,773 0 61,773 0 61,773 61,7732022 2021Program 2018, Number Number Number Number 2019 and 2020 outstanding outstanding outstanding outstanding options (Co-wor-at Jan 1, Granted/at Dec 31, at Jan 1, Granted/at Dec 31, ker LTIP 2018)2022forfeited20222021forfeited2021CEO Carl-Johan 300,000 -100,000 200,000 300,000 0 300,000DalsgaardOther senior 703,750 -150,000 553,750 703,750 0 703,750executivesOther employees 235,850 -50,000 185,850 235,850 0 235,850Total 1,239,600 -300,000 939,600 1,239,600 0 1,239,6002022 2021Number Number Number Number Program 2021 outstanding outstanding outstanding outstanding options (Co-wor-at Jan 1, Granted/at Dec 31, at Jan 1, Granted/at Dec 31, ker LTIP 2021)2022forfeited20222021forfeited2021CEO Carl-Johan 100,000 100,000 200,000 0 100,000 100,000DalsgaardOther senior 436,000 480,000 916,000 0 436,000 436,000executivesOther employees 229,933 407,850 637,783 0 271,600 271,600Total 765,933 987,850 1,753,783 0 807,600 807,600For information about other senior executives, see Note 7 \"Employees and personnel costs\".", "dimensions": { "concept": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-634-2": { "value": "Note 9 Other operating income2022 2021Exchange rate gains 1,553 1,094Total other operating income 1,553 1,094Note 10 Other operating expenses2022 2021Exchange rate losses 4,784 2,492Total other operating expenses 4,784 2,492", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-634-3": { "value": "Note 9 Other operating income2022 2021Exchange rate gains 1,553 1,094Total other operating income 1,553 1,094", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-636-2": { "value": "Note 11 Financial income2022 2021Financial assets measured at fair value through profit and lossExchange rate gains currency accounts 1,483 0Total 1,483 0Financial assets measured at amortized costInterest income short-term investments 913 646Total interest income calculated using the effective interest method 913 646Total disclosed in net financial income/expenses 2,395 646Note 12 Financial expenses2022 2021Financial assets measured at fair value through profit and lossChange in value for long-term investments -468 -2,121Exchange rate losses currency accounts 0 -431Total -468 -2,552Financial liabilities measured at amortized costInterest expenses other financial liabilities -8 -11Total interest expenses calculated using the effective interest method -8 -11Total disclosed in net financial income/expenses -476 -2,563", "dimensions": { "concept": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-636-3": { "value": "Note 11 Financial income2022 2021Financial assets measured at fair value through profit and lossExchange rate gains currency accounts 1,483 0Total 1,483 0Financial assets measured at amortized costInterest income short-term investments 913 646Total interest income calculated using the effective interest method 913 646Total disclosed in net financial income/expenses 2,395 646", "dimensions": { "concept": "ifrs-full:DisclosureOfFinanceIncomeExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-636-4": { "value": "Note 11 Financial income2022 2021Financial assets measured at fair value through profit and lossExchange rate gains currency accounts 1,483 0Total 1,483 0Financial assets measured at amortized costInterest income short-term investments 913 646Total interest income calculated using the effective interest method 913 646Total disclosed in net financial income/expenses 2,395 646Note 12 Financial expenses2022 2021Financial assets measured at fair value through profit and lossChange in value for long-term investments -468 -2,121Exchange rate losses currency accounts 0 -431Total -468 -2,552Financial liabilities measured at amortized costInterest expenses other financial liabilities -8 -11Total interest expenses calculated using the effective interest method -8 -11Total disclosed in net financial income/expenses -476 -2,563", "dimensions": { "concept": "ifrs-full:DisclosureOfInterestIncomeExpenseExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-636-5": { "value": "Note 11 Financial income2022 2021Financial assets measured at fair value through profit and lossExchange rate gains currency accounts 1,483 0Total 1,483 0Financial assets measured at amortized costInterest income short-term investments 913 646Total interest income calculated using the effective interest method 913 646Total disclosed in net financial income/expenses 2,395 646", "dimensions": { "concept": "ifrs-full:DisclosureOfInterestIncomeExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-637-4": { "value": "Note 12 Financial expenses2022 2021Financial assets measured at fair value through profit and lossChange in value for long-term investments -468 -2,121Exchange rate losses currency accounts 0 -431Total -468 -2,552Financial liabilities measured at amortized costInterest expenses other financial liabilities -8 -11Total interest expenses calculated using the effective interest method -8 -11Total disclosed in net financial income/expenses -476 -2,563", "dimensions": { "concept": "ifrs-full:DisclosureOfFinanceCostExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-638-2": { "value": "Not 13 Tax2022 2021Current tax 0 0Change in deferred tax regarding temporary differences 384 254Recognized tax 384 254Reconciliation of effective tax rates 2022 2021Loss before tax -288,806 -296,735Tax according to applicable tax rate 20.6% (20.6%) 59,494 61,127Non-deductable expenses -682 -95Tax effect non-taxable income 0 1,118Tax effect unrecognized tax assets -58,428 -61,896Change in deferred tax 384 254Recognized tax 384 254Effective tax rate 0% 0%The group has no tax items that are recognized in other comprehensive income, but there are issue costs booked directly against shareholder\u2019s equity.Information about deferred tax liabilitiesIn the table below, the tax effect of the temporary differences is specified: 2022 2021 Deferred tax liabilityDec 31 Dec 31Intangible assets 641 1,026Tax provision for pension premium 264 184Carrying amount 905 1,210Tax loss carryforwardsTax loss carryforwards for which deferred tax assets have not been recognized in the balance sheet amounted to 1,023,731 KSEK (727,791 KSEK). These carryforwards have no time limit. Deferred tax assets have not been recognized for these items, as it is unlikely that the group in a foreseeable future will utilize them to offset future taxable profits. For further information about tax loss carryforwards, see Note 2 \"Judgements and accounting estimates\".", "dimensions": { "concept": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-638-3": { "value": "Not 13 Tax2022 2021Current tax 0 0Change in deferred tax regarding temporary differences 384 254Recognized tax 384 254Reconciliation of effective tax rates 2022 2021Loss before tax -288,806 -296,735Tax according to applicable tax rate 20.6% (20.6%) 59,494 61,127Non-deductable expenses -682 -95Tax effect non-taxable income 0 1,118Tax effect unrecognized tax assets -58,428 -61,896Change in deferred tax 384 254Recognized tax 384 254Effective tax rate 0% 0%The group has no tax items that are recognized in other comprehensive income, but there are issue costs booked directly against shareholder\u2019s equity.Information about deferred tax liabilitiesIn the table below, the tax effect of the temporary differences is specified: 2022 2021 Deferred tax liabilityDec 31 Dec 31Intangible assets 641 1,026Tax provision for pension premium 264 184Carrying amount 905 1,210Tax loss carryforwardsTax loss carryforwards for which deferred tax assets have not been recognized in the balance sheet amounted to 1,023,731 KSEK (727,791 KSEK). These carryforwards have no time limit. Deferred tax assets have not been recognized for these items, as it is unlikely that the group in a foreseeable future will utilize them to offset future taxable profits. For further information about tax loss carryforwards, see Note 2 \"Judgements and accounting estimates\".", "dimensions": { "concept": "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-639-2": { "value": "Note 14 Earnings per shareEarnings per share before and after dilution 2022 2021Profit for the year attributable to shareholders of the parent company -288,423,230 -296,480,577Average number of ordinary shares 72,214,440 69,678,461Earnings per share before and after dilution -3.99 -4.25The average number of outstanding shares has been adjusted for bonus shares in new stock issued targeted towards existing shareholders. Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding for the dilution effect from all potential ordinary shares. These potential ordinary shares are attributable to the options and share awards allocated to senior execu-tives, other employees and certain board members during the years 2018-2022. For further information, see Note 8 \"Share-based payments\". If there is a loss for the year, the options are not treated as dilutive. Neither are the options considered dilutive if the exercise rate, including the addition of the value of remaining future services to be recognized during the vesting period, exceeds the average trading price for the period. There is no dilution effect for potential ordinary shares as there was a loss for the year, as demonstrated above.For more information about the changes of the number of outstanding shares, see Note 24 \"Sharehold-ers\u2019 equity\".", "dimensions": { "concept": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-640-2": { "value": "Note 15 Patents, licenses and similar rights2022 2021 Dec 31Dec 31Opening cost 75,192 75,192Additions for the year 6,000 0Disposals -2,000 0Closing accumulated cost 79,192 75,192Opening amortizations -7,765 -4,437Amortizations for the year -3,327 -3,328Closing accumulated amortizations -11,092 -7,765Closing carrying amount 68,100 67,427Amortizations Amortization refers to previously acquired intangible assets. This consists of a patent portfolio related to C21, whose main patent expires in the United States in September 2024. Amortization began in Septem-ber 2019 and is amortized over its estimated useful life, which is the remaining patent period. Amortization has not yet begun for the group's other intangible assets.Impairment testingTo test the value of acquired intangible assets, Vicore uses a probability-adjusted discounted cash flow model based on fair value. The value in use for C21, IMiD and C106 is determined by calculating the present value of the estimated future cash flows and adjusting these in order to take the development risk into account. The valuation considers the cash flows over the projects\u2019 estimated remaining useful life, but does not involve calculation of any residual value thereafter. The methodology used is an accepted one for impairment testing within the biopharmaceutical industry. The measurement is attributed to Level 3 in the fair value hierarchy and comprises the material assumptions specified below: \u2022 Revenue- and cost forecasts for C21 stretches over 7 years for the US and 10 years for the EU and Japan, that is, during the period in which the company has orphan drug protection in each market. Revenue- and cost forecasts for IMiD and C106 stretches over 20 years. \u2022 Revenue is calculated using estimations based on available data of different types considered indica-tors, e.g. forecasts of total market size, growth, anticipated market share of the product, competition from rival products and assessed price level. Market, growth, anticipated market share of the product and assessed price level is derived from secondary sources, accepted industry assumptions and assumptions made by Vicore.\u2022 Costs comprise development expenditures as well as direct and indirect project costs based on Vicore\u2019s business plan. Operating margins are derived from secondary sources, accepted industry assumptions and assumptions made by Vicore.\u2022 The present value of the cash flows is calculated and adjusted to reflect the probability of success for the project. This probability is based on accepted assumptions regarding the possibility for a corre-sponding product to go to market from the current development stage. The probability of success for C21 is estimated at 25.6%, IMiD at 7.2%, and C106 at 15.3%.\u2022 The weighted average pre-tax cost of capital has been estimated at 14% (14%). The most critical assumptions mainly consist of assumptions made about market size, market share and price level. As with many pharmaceutical development projects, the results of the development work may be binary in the sense that the project can either be developed according to plan or must be cancelled altogether. Where appropriate, the valuation has been calibrated against completed share issues with external investors.The impairment assessment for December 31, 2022, has not demonstrated a need for any impairments. No reasonable changes in the assumptions and estimates made would lead to an impairment.", "dimensions": { "concept": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-640-3": { "value": "Note 15 Patents, licenses and similar rights2022 2021 Dec 31Dec 31Opening cost 75,192 75,192Additions for the year 6,000 0Disposals -2,000 0Closing accumulated cost 79,192 75,192Opening amortizations -7,765 -4,437Amortizations for the year -3,327 -3,328Closing accumulated amortizations -11,092 -7,765Closing carrying amount 68,100 67,427Amortizations Amortization refers to previously acquired intangible assets. This consists of a patent portfolio related to C21, whose main patent expires in the United States in September 2024. Amortization began in Septem-ber 2019 and is amortized over its estimated useful life, which is the remaining patent period. Amortization has not yet begun for the group's other intangible assets.Impairment testingTo test the value of acquired intangible assets, Vicore uses a probability-adjusted discounted cash flow model based on fair value. The value in use for C21, IMiD and C106 is determined by calculating the present value of the estimated future cash flows and adjusting these in order to take the development risk into account. The valuation considers the cash flows over the projects\u2019 estimated remaining useful life, but does not involve calculation of any residual value thereafter. The methodology used is an accepted one for impairment testing within the biopharmaceutical industry. The measurement is attributed to Level 3 in the fair value hierarchy and comprises the material assumptions specified below: \u2022 Revenue- and cost forecasts for C21 stretches over 7 years for the US and 10 years for the EU and Japan, that is, during the period in which the company has orphan drug protection in each market. Revenue- and cost forecasts for IMiD and C106 stretches over 20 years. \u2022 Revenue is calculated using estimations based on available data of different types considered indica-tors, e.g. forecasts of total market size, growth, anticipated market share of the product, competition from rival products and assessed price level. Market, growth, anticipated market share of the product and assessed price level is derived from secondary sources, accepted industry assumptions and assumptions made by Vicore.\u2022 Costs comprise development expenditures as well as direct and indirect project costs based on Vicore\u2019s business plan. Operating margins are derived from secondary sources, accepted industry assumptions and assumptions made by Vicore.\u2022 The present value of the cash flows is calculated and adjusted to reflect the probability of success for the project. This probability is based on accepted assumptions regarding the possibility for a corre-sponding product to go to market from the current development stage. The probability of success for C21 is estimated at 25.6%, IMiD at 7.2%, and C106 at 15.3%.\u2022 The weighted average pre-tax cost of capital has been estimated at 14% (14%). The most critical assumptions mainly consist of assumptions made about market size, market share and price level. As with many pharmaceutical development projects, the results of the development work may be binary in the sense that the project can either be developed according to plan or must be cancelled altogether. Where appropriate, the valuation has been calibrated against completed share issues with external investors.The impairment assessment for December 31, 2022, has not demonstrated a need for any impairments. No reasonable changes in the assumptions and estimates made would lead to an impairment.", "dimensions": { "concept": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-642-2": { "value": "Note 16 Equipment 2022 2021 Dec 31Dec 31Opening cost 147 147Closing accumulated cost 147 147Opening depreciations -63 -34Depreciations for the year -30 -29Closing accumulated depreciations -93 -63Closing carrying amount 54 84", "dimensions": { "concept": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-643-2": { "value": "Note 17 Long-term investments2022 2021 Dec 31Dec 31Opening carrying amount 5,409 7,530Change in value in profit/loss -469 -2,121Reclassification to short-term investments -4,940 0Closing carrying amount 0 5,409Vicore holds as of December 31, 2022, a total of 91,829 shares in I-Tech AB (publ). The holdings were reclas-sified in December, 2022, to short-term investments. The holdings were divested on January 4, 2023. ", "dimensions": { "concept": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-644-2": { "value": "Note 18 Financial assets and liabilitiesFinancial assets and liabilities at December 31, 2022Financial assets/ liabilities Financial assets/ Total measured at fair value liabilities measured carrying through profit and lossat amortized costamountFinancial assetsOther current receivables 0 338 338Short-term investments 4,940 0 4,940Cash and cash equivalents 0 256,803 256,803Total 4,940 257,141 262,081Financial liablilitiesContract liability 0 64 64Trade payables 0 23,495 23,495Other liabilities 0 70 70Accrued expenses 0 14,381 14,381Total 0 38,010 38,010The maximum credit risk of the financial assets consists of the net amounts of the reported values in the table above The group has not received any pledged assets for the financial net assets.Financial assets and liabilities at December 31, 2021Financial assets/ liabilities Financial assets/ Total measured at fair value liabilities measured at carrying through profit and lossamortized costamountFinancial assetsLong-term investments 5,409 0 5,409Other current receivables 0 60 60Accrued income 0 281 281Short-term investments 0 77,000 77,000Cash and cash equivalents 0 294,199 294,199Total 5,409 371,540 376,949Financial liablilitiesContract liability 0 320 320Trade payables 0 23,984 23,984Accrued expenses 0 35,311 35,311Total 0 59,615 59,615The maximum credit risk of the financial assets consists of the net amounts of the reported values in the table above The group has not received any pledged assets for the financial net assets.Fair value measurementIFRS 13, Fair Value Measurement contains a valuation hierarchy regarding inputs to the measurements. This measurement hierarchy is divided into three levels, which comprise:Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilitiesLevel 2 - Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as price quotations) or indirectly (that is, derived from price quotations)Level 3 - Inputs for the asset or liability that are not based on observable market data (that is, non-observ-able inputs)Long-term investmentsInvestments in financial fixed assets are measured at fair value with changes in value in profit and loss. Investments in listed shares are measured at fair value according to Level 1 in the valuation hierarchy. Listed investments are measured on the basis of their share price on the closing day.Other financial assets and liabilitiesFor other current receivables and liabilities, short-term investments, cash and cash equivalents, trade payables, and accrued income and expenses with a short maturity, the carrying amount is considered a reasonable estimate of the fair value.", "dimensions": { "concept": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-644-3": { "value": "Note 18 Financial assets and liabilitiesFinancial assets and liabilities at December 31, 2022Financial assets/ liabilities Financial assets/ Total measured at fair value liabilities measured carrying through profit and lossat amortized costamountFinancial assetsOther current receivables 0 338 338Short-term investments 4,940 0 4,940Cash and cash equivalents 0 256,803 256,803Total 4,940 257,141 262,081Financial liablilitiesContract liability 0 64 64Trade payables 0 23,495 23,495Other liabilities 0 70 70Accrued expenses 0 14,381 14,381Total 0 38,010 38,010The maximum credit risk of the financial assets consists of the net amounts of the reported values in the table above The group has not received any pledged assets for the financial net assets.Financial assets and liabilities at December 31, 2021Financial assets/ liabilities Financial assets/ Total measured at fair value liabilities measured at carrying through profit and lossamortized costamountFinancial assetsLong-term investments 5,409 0 5,409Other current receivables 0 60 60Accrued income 0 281 281Short-term investments 0 77,000 77,000Cash and cash equivalents 0 294,199 294,199Total 5,409 371,540 376,949Financial liablilitiesContract liability 0 320 320Trade payables 0 23,984 23,984Accrued expenses 0 35,311 35,311Total 0 59,615 59,615The maximum credit risk of the financial assets consists of the net amounts of the reported values in the table above The group has not received any pledged assets for the financial net assets.Fair value measurementIFRS 13, Fair Value Measurement contains a valuation hierarchy regarding inputs to the measurements. This measurement hierarchy is divided into three levels, which comprise:Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilitiesLevel 2 - Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as price quotations) or indirectly (that is, derived from price quotations)Level 3 - Inputs for the asset or liability that are not based on observable market data (that is, non-observ-able inputs)Long-term investmentsInvestments in financial fixed assets are measured at fair value with changes in value in profit and loss. Investments in listed shares are measured at fair value according to Level 1 in the valuation hierarchy. Listed investments are measured on the basis of their share price on the closing day.Other financial assets and liabilitiesFor other current receivables and liabilities, short-term investments, cash and cash equivalents, trade payables, and accrued income and expenses with a short maturity, the carrying amount is considered a reasonable estimate of the fair value.", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-644-4": { "value": "Note 18 Financial assets and liabilitiesFinancial assets and liabilities at December 31, 2022Financial assets/ liabilities Financial assets/ Total measured at fair value liabilities measured carrying through profit and lossat amortized costamountFinancial assetsOther current receivables 0 338 338Short-term investments 4,940 0 4,940Cash and cash equivalents 0 256,803 256,803Total 4,940 257,141 262,081Financial liablilitiesContract liability 0 64 64Trade payables 0 23,495 23,495Other liabilities 0 70 70Accrued expenses 0 14,381 14,381Total 0 38,010 38,010The maximum credit risk of the financial assets consists of the net amounts of the reported values in the table above The group has not received any pledged assets for the financial net assets.Financial assets and liabilities at December 31, 2021Financial assets/ liabilities Financial assets/ Total measured at fair value liabilities measured at carrying through profit and lossamortized costamountFinancial assetsLong-term investments 5,409 0 5,409Other current receivables 0 60 60Accrued income 0 281 281Short-term investments 0 77,000 77,000Cash and cash equivalents 0 294,199 294,199Total 5,409 371,540 376,949Financial liablilitiesContract liability 0 320 320Trade payables 0 23,984 23,984Accrued expenses 0 35,311 35,311Total 0 59,615 59,615The maximum credit risk of the financial assets consists of the net amounts of the reported values in the table above The group has not received any pledged assets for the financial net assets.Fair value measurementIFRS 13, Fair Value Measurement contains a valuation hierarchy regarding inputs to the measurements. This measurement hierarchy is divided into three levels, which comprise:Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilitiesLevel 2 - Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as price quotations) or indirectly (that is, derived from price quotations)Level 3 - Inputs for the asset or liability that are not based on observable market data (that is, non-observ-able inputs)Long-term investmentsInvestments in financial fixed assets are measured at fair value with changes in value in profit and loss. Investments in listed shares are measured at fair value according to Level 1 in the valuation hierarchy. Listed investments are measured on the basis of their share price on the closing day.Other financial assets and liabilitiesFor other current receivables and liabilities, short-term investments, cash and cash equivalents, trade payables, and accrued income and expenses with a short maturity, the carrying amount is considered a reasonable estimate of the fair value.", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-644-5": { "value": "Note 18 Financial assets and liabilitiesFinancial assets and liabilities at December 31, 2022Financial assets/ liabilities Financial assets/ Total measured at fair value liabilities measured carrying through profit and lossat amortized costamountFinancial assetsOther current receivables 0 338 338Short-term investments 4,940 0 4,940Cash and cash equivalents 0 256,803 256,803Total 4,940 257,141 262,081Financial liablilitiesContract liability 0 64 64Trade payables 0 23,495 23,495Other liabilities 0 70 70Accrued expenses 0 14,381 14,381Total 0 38,010 38,010The maximum credit risk of the financial assets consists of the net amounts of the reported values in the table above The group has not received any pledged assets for the financial net assets.Financial assets and liabilities at December 31, 2021Financial assets/ liabilities Financial assets/ Total measured at fair value liabilities measured at carrying through profit and lossamortized costamountFinancial assetsLong-term investments 5,409 0 5,409Other current receivables 0 60 60Accrued income 0 281 281Short-term investments 0 77,000 77,000Cash and cash equivalents 0 294,199 294,199Total 5,409 371,540 376,949Financial liablilitiesContract liability 0 320 320Trade payables 0 23,984 23,984Accrued expenses 0 35,311 35,311Total 0 59,615 59,615The maximum credit risk of the financial assets consists of the net amounts of the reported values in the table above The group has not received any pledged assets for the financial net assets.Fair value measurementIFRS 13, Fair Value Measurement contains a valuation hierarchy regarding inputs to the measurements. This measurement hierarchy is divided into three levels, which comprise:Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilitiesLevel 2 - Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as price quotations) or indirectly (that is, derived from price quotations)Level 3 - Inputs for the asset or liability that are not based on observable market data (that is, non-observ-able inputs)Long-term investmentsInvestments in financial fixed assets are measured at fair value with changes in value in profit and loss. Investments in listed shares are measured at fair value according to Level 1 in the valuation hierarchy. Listed investments are measured on the basis of their share price on the closing day.Other financial assets and liabilitiesFor other current receivables and liabilities, short-term investments, cash and cash equivalents, trade payables, and accrued income and expenses with a short maturity, the carrying amount is considered a reasonable estimate of the fair value.", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-646-2": { "value": "Note 19 Financial risksThrough its operations, Vicore is exposed to various types of financial risk; credit risks, market risks (foreign exchange risk, interest rate risk and other price risks) and liquidity risks (including refinancing risk). The group\u2019s overall risk management objective focuses on the unpredictability of financial markets and strives to minimize potentially unfavorable consequences for the group\u2019s financial position and performance.The Board of Directors has overall responsibility for managing financial risks and internal controls related to financial transactions. Financial risks and transactions are managed centrally by the parent company through the group\u2019s CFO and CEO. The overall objective in terms of financial risks is: to provide cost-effec-tive financing and cash management, to ensure that all payment commitments are processed at the right time, to ensure that all financial transactions are organized in a way that supports the group in achieving the financial key ratios and ensure that risk exposures relating to credit risk, market risks and liquidity risk are reduced to an acceptable level.The Board of Directors establishes written principles both for the overall risk management and for spe-cific areas such as credit risks, foreign exchange risks, interest rate risks, refinancing risks, liquidity risks and the use of derivative instruments and the handling of excess liquidity. The group does not currently use derivatives, but allows hedging of currency in certain situations.", "dimensions": { "concept": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-647-2": { "value": "Credit risk Credit risk is the risk that the group\u2019s counterparty of a financial instrument cannot fulfill its obligation and thereby causes a financial loss for the group. Given the nature of the group\u2019s business, with no foreseen revenues, credit risk is not a material issue at this stage of the company\u2019s development. However, some credit risk exists in the group\u2019s cash management, which is managed through Vicore\u2019s treasury policy.Financial credit risk The financial assets that are covered by provisions for expected credit losses according to the general method consist of cash and cash equivalents. Vicore applies a rating-based method in combination with other known information and forward-looking factors for assessing expected credit losses. The group has defined default as when payment of the claim is 90 days overdue or more, or if other factors indicate a suspension of payments. Significant increase in credit risk has not been considered to exist for any receiv-able or asset on the reporting date. Such assessment is based on whether payment is 30 days overdue or more, or if significant deterioration of the rating occurs, entailing a rating below investment grade. In cases where the amounts are not deemed to be insignificant, a provision for expected credit losses is also recognized for these financial instruments.The assessment has been made that there has been no significant increase in credit risk for any of the group\u2019s financial assets. There counterparties do not have credit ratings, except for cash and cash equivalents where the counterparties have credit risk ratings of AA-, A+ and A.", "dimensions": { "concept": "ifrs-full:DisclosureOfCreditRiskExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-648-2": { "value": "Market risksMarket risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risks are according to IFRS divided into three types: foreign exchange risk, interest rate risk and other price risks. Foreign exchange risk is the market risk with the greatest impact on the group as the financing received shall cover for research and development costs mainly in foreign currencies.The group does not currently have any loans that expose it to interest rate risks. Interest risk may occur in short term cash management, and is regulated by maximum maturities.The group is partly exposed to other price risks from investments in listed shares. However, the risks associated with the investments have not been considered to be significant.", "dimensions": { "concept": "ifrs-full:DisclosureOfMarketRiskExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-652-2": { "value": "Refinancing riskRefinancing risk refers to the risk that cash and cash equivalents are unavailable and that financing can only be obtained partially, not at all or at an elevated cost. If the company's development projects fail or are delayed, it may negatively affect the company's ability to raise external capital. In addition, market conditions, the general availability of capital as well as uncertainty and/or disturban-ces in the capital markets can affect the company's ability to raise, and the availability of, such financing. There is a risk that new capital cannot be raised when needed, that new capital can only be raised at terms and conditions unsatisfactory for the company, or that available capital is not sufficient for the company's development plans and objectives. In the event of one or more risks occurring, it may have significant negative effects on the Company\u2019s financial position in the form of, for example, a significantly increased debt/equity ratio, increased expenses for loans and other financing.Liquidity risk Liquidity risk is the risk that the group will encoun-ter difficulties in fulfilling its obligations related to financial liabilities. The Board of Directors manage liquidity risk by continuously following up the cash flow to reduce liquidity risk and ensure the solvency of the group.Vicore uses rolling forecasts to ensure that the company has sufficient cash assets to meet its operational requirements. This monitoring takes the form of reporting to the Board, whereby outcomes and forecasts are compared with the budget that is produced and approved by the Board each year.Surplus liquidity in Vicore, in excess of what is required to manage working capital requirements, is from time to time invested in interest-bearing current accounts. At the balance sheet date, Vicore had short-term investments in fixed-rate accounts of 0 KSEK (77,000 KSEK). In addition to this, Vicore had bank deposits of 256,803 KSEK (294,199 KSEK) at the balance sheet date.The group\u2019s contractual and undiscounted interest payments and financial liability repayments are shown in the table below. Amounts in foreign currencies have been translated into SEK at the closing rate on the reporting date. Financial instruments with a variable interest rate have been calculated using the interest rate at the reporting date. Liabilities have been included in the earliest period during which repayment may be required. Dec 31, 2022<1 month 1-3 months >3 monthsMaturity analysisContract liability 21 43 0Trade payables 23,446 49 0Other short-term liabilities 70 0 0Accrued expenses 4,856 5,194 4,331Total 28,393 5,286 4,331Dec 31, 2021<1 month 1-3 months >3 monthsMaturity analysisContract liability 21 42 257Trade payables 23,785 198 0Accrued expenses 0 13,934 21,377Total 23,806 14,174 21,634Capital managementThe group\u2019s goals regarding the capital structure are to ensure financing of the company\u2019s development and business plan. Equity or financing related to equity is expected to be the most realistic and possible alternative in the near future.No change occurred in the group\u2019s capital management during the year. None of the group companies are subject to external capital requirements.", "dimensions": { "concept": "ifrs-full:DisclosureOfLiquidityRiskExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-655-2": { "value": "Note 20 Prepaid expenses and accrued income2022 2021 Dec 31Dec 31Prepaid rental charges 109 214Prepaid insurances 626 591Prepaid research and development expenses 4,538 3,123Other prepaid expenses 594 1,106Total 5,867 5,034", "dimensions": { "concept": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-656-2": { "value": "Note 21 Short-term investments2022 2021 Dec 31Dec 31Fixed-rate account, SBAB 0 77,000Accrued interest income 0 281Reclassification from long-term investments (I-Tech AB) 4,940 0Total 4,940 77,281", "dimensions": { "concept": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-657-2": { "value": "Note 22 Cash and cash equivalents 2022 2021 Available balancesDec 31Dec 31SEK 256,799 232,568EUR 4 61,631Total 256,803 294,199", "dimensions": { "concept": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-658-2": { "value": "Note 23 Group companiesShare of equity and voting rights2022 2021 Company Principal activityDec 31Dec 31Vicore Pharma Holding AB Own and manage shares in subsidiaries Parent companyResearch and development of Vicore Pharma AB100% 100%pharmaceutical productsResearch and development of INIM Pharma AB100% 100%pharmaceutical products", "dimensions": { "concept": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-659-3": { "value": "Note 24 Shareholders\u2019 equityShare capital and other contributed capitalNumber of Other contributed SEKordinary shares Share capitalcapitalAt January 1, 2021 60,418,239 30,209,119 702,052,950Issue in kind, November 2, 2020, registered February 142,054 71,027 2,928,97322, 2021New share issue, February 22, 2021, registered March 11,200,000 5,600,000 312,821,8959, 2021Share-based payments 0 0 3,861,698At December 31, 2021 71,760,293 35,880,146 1,021,665,516At January 1, 2022 71,760,293 35,880,146 1,021,665,516New share issue, June 17, 2022, registered June 28, 87,686 43,843 2,956,1572022New share issue, December 8, 2022, registered Decem-10,000,000 5,000,000 182,292,382ber 28, 2022Share-based payments 0 0 3,897,141At December 31, 2022 81,847,979 40,923,989 1,210,811,196", "dimensions": { "concept": "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-660-2": { "value": "Note 25 Other provisions2022 2021 Social security contributions related to share-based incentive programsDec 31Dec 31Opening amount 752 6,177Provisions for the year 975 -5,425Total 1,727 752For more information about incentive programs, see Note 8 \"Share-based payments\".", "dimensions": { "concept": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-661-2": { "value": "Note 26 Accrued expenses and deferred income2022 2021 Dec 31Dec 31Accrued personnel-related expenses 3,582 4,644Accrued expenses, research and development 13,166 35,036Accrued expenses, other 1,473 459Total 18,221 40,139Note 27 Supplementary information to the cash flow statement2022 2021 Adjustment for items not included in the cash flowDec 31 Dec 31Depreciations 3,612 3,598Loss on disposal of intangible asset 2,000 0Incentive programs, payroll expenses 3,897 3,862Incentive programs, social security contributions 975 -5,425Provision for payroll tax, pension premium 76 64Total 10,560 2,099", "dimensions": { "concept": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-663-3": { "value": "Note 28 Related-party transactionsRelated parties are defined as individuals with holdings of more than ten percent, members of the group\u2019s senior management, meaning the Board of Directors and senior executives, as well as their immediate family members. For information about remuneration to senior executives and the Board of Directors, see Note 7 \"Employees and personnel costs\".", "dimensions": { "concept": "ifrs-full:DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-664-2": { "value": "Note 29 Contingent liabilitiesBelow a summary of material agreements which the company has entered into during the most recent years:Agreement with Emeriti Bio ABVicore Pharma AB (\"Vicore Pharma\") entered into a collaboration and development agreement with Emeriti Bio AB on August 24, 2016, which was expanded on November 1, 2017. The main purpose of the agreement is to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor (AT2R). On November 2, 2020, the parties expanded their collaboration and development agreement in connection with the acquisition of a number of new intellectual proporty rights as part of the development of new AT2R agonists from HaLaCore Pharma AB, where HaLaCore Pharma AB became a new party to the agreement. The agreement is valid until there is no longer any obligation to pay Emeriti Bio AB and HaLaCore Pharma AB. For Emeriti Bio AB\u2019s and HaLaCore Pharma AB's development work, Vicore Pharma pays con-sultancy fees, possible milestone compensation subject to achievement of predefined development goals. Vicore Pharma owns all results. The total maximum payments in the form of milestone compensation under the agreement is limited to 49.5 MSEK. In 2020, a milestone payment of 1,000 KSEK (250 KSEK) was paid to Emeriti Bio AB in connection with the filing of a patent application by Vicore Pharma. As compensation for the acquisition of intellectual property rights, HaLaCore received a one-time payment of 6 MSEK in 2020, divided between 3 MSEK in cash and 142,054 newly issued shares in Vicore, corresponding to approximately 3 MSEK. In June 2022, a milestone payment of approximately 6 MSEK was paid to Emeriti Bio AB and HaLaCore Pharma AB in connection with the first subject being dosed in the phase 1 study with C106. This is reported in Note 15 \"Patents, licenses and similar rights\".Agreement with Alex Therapeutics ABVicore Pharma AB (\"Vicore Pharma\") entered into a collaboration and development agreement with Alex Therapeutics on April 23, 2021. The main purpose of the agreement is to develop a digital app in interstitial lung diseases, such as IPF. Within the scope of the collaboration and development agreement, Vicore Pharma pays certain milestone payments if the collaboration leads to predetermined development goals as well as royalties on sales. At the entering of the agreement, Vicore paid a one-time payment amounting to 0.8 MEUR.", "dimensions": { "concept": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "pp-value-665-2": { "value": "Note 30 Events after the balance sheet date\u2022 In January, Vicore divested its entire holding of 91,829 shares in I-Tech AB (publ). As of December 31, 2022, the value of the financial asset was approximately 4.9 MSEK. \u2022 In March, Vicore was awarded Innovation Passport designation by the UK regulatory agency MHRA (Medicines and Healthcare products Regulatory Agency) for C21 in IPF. ", "dimensions": { "concept": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } }, "f20565": { "value": "Vicore Pharma Holding AB", "dimensions": { "concept": "ifrs-full:ExplanationOfChangeInNameOfReportingEntityOrOtherMeansOfIdentificationFromEndOfPrecedingReportingPeriod", "language": "en", "entity": "scheme:549300KTNBPTZLF01130", "period": "2022-01-01T00:00:00/2023-01-01T00:00:00" } } } }